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Summary 
 
Malaria is a disease caused by protozoan parasites of the genus Plasmodium and is 
responsible for about half a billion diseases cases and 2-3 million deaths each year. Much 
of the parasite’s success to establish persistent infections is attributed to evasion of the 
human immune defense system through antigenic variation and increasing development of 
resistance to all currently available antimalarial drugs except the artemisinins. The 
difference in structure and mode of action of the artemisinins underlines the fact that new 
antimalarial drugs – with differential modes of action – are an urgent priority in order to 
circumvent plasmodial resistance mechanisms in the absence of effective vaccines or 
vector control measures.  
By means of rational drug design and re-evaluation of an ancient antimalarial drug, three 
new drug development strategies against the deadliest malarial parasite, Plasmodium 
falciparum, were developed within the frame of this thesis in order to design possible new 
mechanism drugs and prevent resistance development to artemisinin.  
First, a complete functional glutathione-dependent glyoxalase (Glo) detoxification system 
– comprising a cytosolic GloI (cGloI), a GloI-like protein (GILP) and two GloIIs (cytosolic 
GloII named cGloII, and tGloII preceded by a targeting sequence) – was characterized in 
direct comparison with the isofunctional human host enzymes. Kinetic and structural 
similarities of enzymes of both systems were described; however, striking differences – 
especially for the GloIs – were also detected which could be exploited for drug 
development. Various S-(N-hydroxy-N-arylcarbamoyl)glutathiones tested as P. falciparum 
Glo inhibitors were found to be active in the lower nanomolar range and could be used as 
lead structures in the development of more selective inhibitors of the P. falciparum 
glyoxalase system (Akoachere et al., 2005).  
Secondly, the characterization of the mode of inhibition of three promising inhibitors of the 
previously-validated drug target P. falciparum thioredoxin reductase (PfTrxR) is reported 
in this thesis. The enzyme is a homodimeric flavoenzyme which reduces thioredoxin (Trx) 
via a C-terminally located CysXXXXCys pair. In this respect PfTrxR differs significantly 
from its human counterpart which bears a Cys-Sec redox pair at the same position. PfTrxR 
is essentially involved in antioxidant defence and redox regulation of the parasite and has 
been validated as a drug target. The inhibitors, 4-nitro-2,1,3-benzothiadiazole (IC50 on 
PfTrxR = 2 µM), 6,7-nitroquinoxaline (IC50 on PfTrxR = 2 µM), and bis-(2,4-
Summary XVIII 
dinitrophenyl)sulfide (IC50 on PfTrxR = 0.5 µM), showed uncompetitive inhibition with 
respect to both substrates, NADPH and thioredoxin. All three inhibitors were active in the 
lower micromolar range on the chloroquine resistant P. falciparum strain K1. 4-Nitro-
2,1,3-benzothiadiazole was antagonistic with known antimalarials suggesting that the 
inhibitor uses similar routes of uptake and/or acts on related targets or biochemical 
pathways (Andricopulo et al., 2005; Andricopulo et al., submitted).  
Lastly and most importantly, the renaissance of interest in the ancient antimalarial drug 
methylene blue (MB) led to the identification of a potential artemisinin-based combination 
therapy (ACT). A strong synergistic action of MB and artemisinin might be capable of 
fighting resistant P. falciparum parasites in the field. MB is active against all blood stages 
of both chloroquine (CQ)-sensitive and CQ-resistant P. falciparum strains with IC50 values 
in the lower nanomolar range. Ring stages showed the highest susceptibility. As 
demonstrated by high performance liquid chromatography / tandem mass spectrometry on 
different cell culture compartments, MB accumulates in malarial parasites. In drug 
combination assays, MB was found to be antagonistic with CQ and other quinoline 
antimalarials like piperaquine and amodiaquine; with mefloquine and quinine MB showed 
additive effects. In contrast, synergistic effects of MB with artemisinin, artesunate, and 
artemether were observed for all tested parasite strains. Artemisinin/MB concentration 
combination ratios of 3:1 were found to be advantageous demonstrating that the 
combination of artemisinin with a smaller amount of MB can be recommended for 
reaching maximal therapeutic effects. In vitro data reported here indicate that combinations 
of MB with artemisinin (derivatives) might be a promising option for treating drug 
resistant malaria. Resistance development under this drug combination is unlikely to occur 
(Akoachere et al., in press). 
 
Taken together, the results support the feasibility of the rational development of new 
potential antimalarial drugs. In combination with existing and other promising new 
malarial-control measures, new antimalarial drugs could greatly contribute to reducing the 
intolerable global burden of this disease. 
 
 
Zusammenfassung XIX 
Zusammenfassung 
Malaria ist eine parasitäre Infektionskrankheit, die von Protozoen der Gattung Plasmodium 
hervorgerufen wird. Pro Jahr gibt es über 500 Millionen Krankheitsfälle/Neuinfektionen 
mit 2-3 Millionen Todesfällen. Ein wichtiger Punkt in der Pathogenese der Malaria ist die 
Ausbildung persistierender Infektionen. Antigenetische Variation ermöglicht es dem 
Parasiten, das menschliche Immunsystem zu umgehen. Weiterhin sind Plasmodien in der 
Lage, auf die eingesetzten Malariamittel mit rascher Resistenzentwicklung zu reagieren. 
Deshalb kommen Neu- und Weiterentwicklung von Medikamenten in der Bekämpfung der 
Malaria neben Impfstoffentwicklung und Insektiziden Massnahmen gegen  den Vektor 
eine zentrale Rolle zu. Eine Ausnahme in der zunehmenden Resistenzproblematik bildet 
Artemisinin, welches eine andere chemische Zusammensetzung und einen anderen 
Wirkmechanismus als andere gegenwärtige Malariamittel aufweist. 
In Rahmen dieser Doktorarbeit wurden drei neue Arzneimittelentwicklungs-Strategien 
gegen den gefährlichsten human Malariaereger, P. falciparum, verfolgt. Dies erfolgte 
anhand von rationaler Medikamententwicklung bzw. durch eine Neubewertung ehemaliger 
Malariamittel mit dem Ziel, mögliche neue Wirkmechanismen aufzuzeigen und 
Resistenzentwicklung bei Artemisinin zu verhindern.  
Der erste dieser verschiedenen Angriffspunkte war die Charakterisierung neuer 
Arzneimittelzielmoleküle im Plasmodium-Stoffwechsel. Dies umfasst die 
Charakterisierung eines Glutathion-abhängigen Glyoxalase (Glo) Systems im Vergleich 
zum isofunktionellen humanen System. Dieses System hat eine zentrale Rolle im 
Entgiftungsstoffwechsel der Parasiten und besteht aus einer cytosolischen GloI (cGloI), 
einem Glo-I ähnlichen Protein (GILP), zwei GloII (cytosolische GloII (cGloII) sowie 
tGloII mit einer vorangestellten Targeting-Sequenz). Hier werden kinetische und 
strukturelle Ähnlichkeiten im humanen und Plasmodien-System beschrieben und im Sinne 
einer Überprüfung als möglicher Arzneimittel-Angriffsort Verschiedenheiten aufgezeigt 
(vor allem bei GloI). Verschiedene S-(N-Hydroxy-N-Arylcarbamoyl)Glutathion 
Verbindungen  wurden als Inhibitoren der Glyoxalasen an P. falciparum getestet, sie waren 
im niederen nanomolaren Bereich aktiv. Somit können diese Verbindungen als 
Leitsubstanzen für die Entwicklung selektiver Inhibitoren des P. falciparum-Glyoxalase 
Systems dienen (Akoachere et al., 2005). 
Zusammenfassung XX 
Ein zweiter zentraler Punkt dieser Doktorarbeit ist die Charakterisierung des 
Wirkmechanismus von drei vielversprechenden Inhibitoren der bereits als Arzneimittel-
Zielmolekül validierten P. falciparum Thioredoxinreduktase (PfTrxR). Es handelt sich um 
ein homodimeres Flavoenzym, welches Thioredoxin mit Hilfe eines C-terminalen 
CysXXXXCys-Motives reduziert. Hierbei unterscheidet es sich vom humanen Enzym, 
welches an der gleichen Position ein Cys-Sec Redoxpaar beinhaltet. PfTrxR ist essentiell 
involviert in antioxidative Abwehrmechanismen und Redoxhomöostase im 
Plasmodienstoffwechsel. Die Inhibitoren 4-Nitro-2,1,3-Benzothiadiazol (IC50 für PfTrxR = 
2 µM), 6,7-Nitroquinoxalin (IC50 = 2 µM) und Bis-2,4-Dinitrophenyl)sulfid (IC50 = 0,5 
µM) zeigen eine unkompetitive Hemmung für die beiden Substrate NADPH und 
Thioredoxin. Alle drei Inhibitoren sind aktiv im niederen mikromolaren Bereich bei dem 
choroquinresistenten P. falciparum Stamm K1. 4-Nitro-2,1,3-Benzothiadiazol zeigt einen 
antagonistischen Wirkmechanismus mit anderen bekannten Malariamitteln; dies bedeutet, 
dass dieser Hemmstoff entweder einen ähnlichen Aufnahmemechanismus besitzt und/oder 
an verschiedenen Molekülen bzw. biochemischen Stoffwechselwegen angreift  
(Andricopulo et al., 2005; Andricopulo et al., submitted).  
Im Sinne einer Neubewertung früherer Arzneimittel gegen Malaria fokussiert meine 
Doktorarbeit auf Methylenblau (MB) in Bezüg auf eine mögliche Artemisinin-gestützte 
Kombinationstherapie (ACT: Artemisinin-based combination therapy). Diese Kombination 
aus zwei Antimalariamitteln ist ein möglicher Weg, Resistenzenentwicklungen bei 
Plasmodium zu vermeiden. Methylenblau ist aktiv gegen alle Blutstadien von Plasmodium 
sowohl an chloroquinresistenten Stämmen mit IC50-Werten im niedermolaren Bereich. 
Hierbei zeigen Ringstadien die höchste Empfindlichkeit. Darüberhinaus akkumuliert MB 
in verschiedenen Zellkompartimenten, dies konnte mit Hilfe von Hochdurchsatz-
Flüssigkeits-Chromatographie bzw. Tandem-Massen-Spektrometrie gezeigt werden. In 
Arzneimittel-Kombinations-Assays konnte nachgewiesen werden, dass MB antagonistisch 
zu Chloroquin und anderen Quinolinen wie Piperaquin und Amodiaquin wirkt, während es 
mit Mefloquin und Quinine einen additiven Effekt zeigt. Im Gegenteil dazu besitzt MB 
einen synergistischen Effekt mit Artemisinin, Artesunat und Artemether in allen getesteten 
Plasmodienstämmen. Ein Konzentrationsverhältnis von 3:1 zwischen Artemisinin und MB 
hat sich als vorteilhaft erwiesen. Dies verdeutlicht, dass geringe Mengen von MB 
empfohlen werden können, um maximalen therapeutischen Effekt zu erzielen. Diese hier 
berichteten in vitro-Daten unterstützen die Thesen, dass die Kombination aus Artemisinin 
(bzw. Artemisininderivaten) und MB eine vielversprechende Möglichkeit in der 
Zusammenfassung XXI 
Behandlung therapieresistenter Malariafälle bieten kann. Weiterhin ist eine 
Resistenzentwicklung gegen die Arzneimittelkombination unwahrscheinlich (Akoachere et 
al., 2005). 
Zusammenfassend kann man sagen, dass diese Resultate die Eignung der rationalen 
Arzneimittelentwicklung für neue Antimalariamittel unterstreichen. In Kombination mit 
existierenden Arzneimitteln und zusammen mit anderen Kontrollmechanismen können 
neue Antimalariamittel dazu beitragen, die intolerierbare, weltweite Bedrohung durch 
Malaria zu verringern. 
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1 Introduction and Rationale 
 
1.1 The disease 
Malaria is a protozoan disease caused in humans by four species of the genus Plasmodium 
(P. falciparum, P. vivax, P. ovale, and P. malariae) and is transmitted by the bite of an 
infected female mosquito of the genus Anopheles. Malaria is today one of the most 
important parasitic diseases of man as it is responsible for approximately a million deaths 
and about 500 million incidences of disease each year. The different strains of Plasmodium 
are responsible for different patterns of the characteristic fevers typical of the disease: P. 
falciparum (malaria tropica), P. vivax (malaria tertiana), P. malariae (malaria tertiana), and 
P. ovale (malaria quartana). Plasmodium vivax and P. falciparum infections are the most 
common. P. falciparum is responsible for the most deadly type of malaria infection with 
children under the age of 5 being most of its victims. P. vivax and P. ovale form resting 
stages in the liver (hypnozoites) which once reactivated can cause a clinical relapse of the 
disease many months after the initial event. Malaria in animals and birds is caused by other 
Plasmodium spp. However, P. knowlesii which normally causes the infection in monkeys 
has also been responsible for cases of the disease in humans (Singh et al., 2004). 
 
 
Figure 1:  Geographic distribution of malaria around the world. 
Malaria is endemic to tropical and subtropical regions (http://www.phac-
aspc.gc.ca/publicat/ccdr-rmtc/96vol22/dr2220ed.html) 
 
Areas in which malaria has disappeared and never existed 
 
Areas with limited risks 
 
Areas of malaria transmission 
Introduction 2
The disease once had a worldwide distribution but it was successfully eliminated from 
many countries with temperate climates during the mid 20th century. Today malaria is 
found throughout the tropical and sub-tropical regions of the world including parts of 
Africa, Asia, Central and South America, Oceania, and certain Caribbean islands (Figure 
1). Almost 90% of all malaria cases occur in Africa necessitating stringent control 
measures within the continent (Snow et al., 2005).  
Malaria is characterized by extreme exhaustion associated with paroxysms of high fever, 
sweating, shaking chills, and anemia (Miller et al., 2002). Several risk groups are found 
among those living in endemic areas who are subject to repeated P. falciparum infections: 
infants and young children suffer particularly from life-threatening anaemia, older children 
from an induced coma (Marsh and Snow, 1999), and primagravida women from severe 
disease related to placental sequestration (Ricke et al., 2000).  Malaria naive travellers, 
either crossing international borders or travelling from malaria-free to malaria-endemic 
areas in their own countries, constitute another risk group, and are susceptible to severe 
disease after acquiring their first infection. There is a number of severe complications that 
are specific to P. falciparum infections. In the nonimmune patient, many of the severe 
complications of P. falciparum – such as cerebral malaria, anemia, hypoglycaemia, renal 
failure, and noncardiac pulmonary oedema – occur in combination or as isolated 
complications (Miller et al., 1994).  
 
1.1.1 The Anopheles vector 
Only female mosquitoes of the genus Anopheles transmit human malaria. The genus 
includes roughly 400 species of Anopheles mosquitoes worldwide, of which 60 species are 
malaria vectors, and some 30 species are of major importance (Bruce-Chwatt, 1985). 
Anopheles gambiae, the principal vector in sub-saharan Africa, is a particular effective 
malaria vector because of its preference for feeding on humans and its long life compared 
with some other anopheline species. The four developmental stages of an anopheline 
mosquito are egg, larva, pupa, and adult (or imago). The adult male feeds on nectar, while 
the female adult feeds primarily upon blood. Females of most Anopheles spp. prefer warm-
blooded animals, predominantly mammals. Some species prefer humans, and are termed 
anthropophagic or anthropophilic. Others prefer animals such as cattle, and are termed 
zoophagic or zoophilic. The time of anopheline feeding is mainly between dusk and dawn. 
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1.1.2 Life cycle of the parasite 
The life cycle of the parasite is complex involving vertebrate and invertebrate hosts as well 
as different locations within each of these hosts. In humans, the malaria parasite enters the 
host when an infected Anopheles mosquito takes a blood meal. The first stage of malaria 
infection in man leads sporozoites of Plasmodium to the liver via blood circulation where 
the sporozoites invade the hepatocytes and begin an asexual phase of reproduction (Figure 
2). This stage lasts on average between 5.5 days (P. falciparum) and 15 days (P. malariae) 
before the hepatic schizonts rupture to release merozoites into the blood stream. In P. vivax 
and P. ovale infections a proportion of the intrahepatic parasites do not develop, but 
instead rest inert as hypnozoites, to awaken weeks or months later, and cause the relapses 
which characterize infections with these two species. The hepatic phase – sometimes called 
the pre-erythrocytic phase – is asymptomatic as only a few liver cells are infected. 
However, considerable asexual reproduction takes place within the hepatocyte and many 
thousands of merozoites are released from each infected hepatocyte. 
Merozoites liberated into the bloodstream invade the erythrocytes by a vigorous wriggling 
or boring motion inside a vacuole composed of the invaginated erythrocyte membrane. 
Once inside the erythrocyte, the parasite lies within the erythrocyte cytosol enveloped by 
its own plasma membrane, and a surrounding parasitophorous vacuolar membrane. Within 
the erythrocytes, the merozoites develop from small ring forms to the trophozoites – 
feeding stages – after about 24 hours of invasion. Approximately 36 hours after merozoite 
invasion (or 54 hours in P. malariae) repeated nuclear division takes place to form the 
schizont or the segmenter form. This then ruptures and the released merozoites (on average 
16 per schizont) reinvade other erythrocytes and start a new cycle. The erythrocytic life 
cycle is approximately 48 hours for P. falciparum, P. vivax and P. ovale, and 72 hours for 
P. malariae. 
After a series of asexual cycles in P. falciparum, a subpopulation of parasites develops into 
sexual forms (male and female gametocytes) which are long lived and motile. Upon 
ingestion of these gametocytes in another blood meal by the mosquito, the gametocytes 
become activated to gametes. Male and female gametes fuse in the insect’s gut to form a 
zygote. The zygote in turn develops into the ookinete, which crosses the wall of the gut and 
forms a sporozoite filled oocyst. When the oocyst bursts, the sporozoites migrate to the 
salivary glands to await inoculation into the next human host upon feeding. These 
mosquitoes normally breed in areas where there is stagnant water such as swamps and 
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during the rainy seasons of African countries but the female mosquito requires a blood 
meal for the maturation of her eggs. 
 
 
Figure 2:  Life cycle of the parasite Plasmodium falciparum.  
Malaria parasites engage in highly specific and varied interactions with cell types of both 
the mammalian host and the mosquito vector (adapted after Wirth, 2003). 
 
 
1.1.3 Pathophysiology of the disease 
The pathophysiology of malaria results from the destruction of erythrocytes, the liberation 
of parasite and erythrocyte material into the circulation, and the host reaction to these 
events. P. falciparum malaria infected erythrocytes also sequester in the microcirculation 
of vital organs, interfering with microcirculatory flow and host tissue metabolism. Malaria 
parasites do induce the release of cytokines, which are responsible for many of the 
symptoms and signs of the infection, particularly fever and malaise (Hunt and Grau, 2003). 
Sequestration of P. falciparum parasites in the brain is thought to be central to the 
pathophysiology of cerebral malaria. 
 
1.1.4 Diagnosis of malaria 
Malaria is diagnosed principally by microscopic examination of the blood for the 
identification of the parasites. Thick and thin blood films are made which are later on 
stained in appropriate staining dyes like Giemsa or Acridine orange. The thick film is 
approximately 30 times more sensitive than the thin film, although sensitivity and 
specificity depend to a great extent on the experience of the microscopist, the quality of the 
slides, stains and microscope, and the time spent examining the slide. Artefacts are 
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common and often confusing. Speciation of malaria at the trophozoite stage is easier on the 
thin film, although gametocytes and schizonts are more likely to be seen on the thick film. 
The thin film is more accurate for parasite counting. A morphological demonstration of P. 
falciparum malaria parasites is shown in Figure 3 below.  
 
 
Figure 3:  Blood stages of P. falciparum (Malaria Manual, 2003). 
 
Although microscopic diagnosis of malaria is the gold standard, it is unreliable outside 
specialized centers. Moreso, the time until results from microscopic examinations become 
available can cause detrimental delays particularly in rapidly fatal P. falciparum infections 
due to a consequent delay in the provision of appropriate therapy (Kain et al., 1998; 
Nüesch et al., 2000). Several rapid malaria tests have been developed and they may be a 
useful diagnostic adjunct to microscopy in centers without major expertise in tropical 
medicine. Polymerase chain reaction (PCR) is a highly sensitive alternative to microscopy, 
but the infrastructure and expertise required preclude its routine use in many health care 
settings (Chiodini, 1998). By using immunochromatographic methods, these tests detect 
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parasite antigens in lysed blood from a fingerprick blood sample and can be performed in 
approximately 15 minutes without special equipment (Chiodini, 1998). Two-band tests 
target histidine-rich protein-2 (HRP-2) and detect P. falciparum only, while the more 
recent 3-band tests also detect other malaria parasites (P. vivax, P. malariae, and P. ovale) 
by using HRP-2 and aldolase combined or parasite lactate dehydrogenase (LDH) as targets 
(Marx et al., 2005). Efforts are needed to optimise sensitivity for the detection of P. vivax 
and improve test performance for P. ovale and P. malariae. 
 
1.1.5 Control 
1.1.5.1 Control through prevention of transmission 
Mosquito control has been at the centre of past efforts to eradicate malaria, mainly through 
the use of the insecticide DDT (dichloro-diphenyl-trichloroethane) for indoor residual 
house-spraying. Facing the ban imposed on DDT, the programme became unsustainable 
despite the notable successes that were achieved. Other insecticides in use include 
carbamates and pyrethroids, against some of which mosquito resistance has been shown to 
develop. Trials of insecticide treated nets (ITNs) have consistently shown reductions in 
overall child mortality and in episodes of clinical malaria (Lengeler, 2004). In emergency 
situations, insecticide-treated tarpaulins have proved very effective and materials that have 
long-acting insecticidal action are being developed. Repellants could provide useful 
protection against malaria, especially in places where vector mosquitoes bite early in the 
evening (Rowland et al., 2004) whereby the use of ITNs has only little protection to offer 
against malaria infection as the mosquito biting precedes local bedtime. The use of 
mixtures or mosaics of insecticides on nets has been a successful approach to prevent 
insecticide resistance.  
Environmental management (including drainage of breeding sites), improvement in house 
design, use of larvivorous fish, and zooprophylaxis have proved effective in some specific 
epidemiological situations but must be based on detailed behavioural knowledge of the 
main local vectors. 
The completion of the sequencing of the Anopheles gambiae genome has provided 
unprecedented opportunities for scientists to study vector-pathogen interactions that are 
central to malaria pathogenesis and treatment. Through integration of advanced and high 
throughput gene expression technologies, the processes of identifying new antigens and 
new targets for insecticide development could be accelerated and hence morbidity and 
mortality caused by malaria could be reduced. 
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1.1.5.2 Control through therapy 
Transmission of the disease malaria warrants a repertoire of infectious gametocytes which 
develop from merozoites in the erythrocytes. Antimalarial drugs which are mostly directed 
to the erythrocytic stages of the parasite control the levels of transmission of the parasite 
by reducing and/or preventing the development of gametocytes from these erythrocytic 
stages. All antimalarial drugs have their liabilities as well as their benefits and could be 
classified into different groups based on their site of antimalarial action. Of particular 
interest are the lysosomal food vacuole (the site of extensive haemoglobin degradation), 
the apicoplast (a plastid organelle thought to originate from a green algal symbiont), an 
acrystate mitochondrion with a limited electron transport system and of course, the cytosol 
(Figure 4).  
 
 
Figure 4: Diagram of P. falciparum trophozoite residing in an erythrocyte.  
The main organelles that are associated with drug targets are highlighted, drawing 
attention to both sites of current antimalarial drug action and new targets that are under 
investigation (Ridley, 2002) 
 
Three broad groups of antimalarial drugs (structures shown in Figure 5) include the aryl 
aminoalcohols or quinoline-related compounds (quinine, chloroquine, amodiaquine, 
mefloquine, halofantrine, lumefantrine, piperaquine, primaquine, and tafenoquine), the 
antifolates (pyrimethamine, sulfadoxine, proguanil, chlorproguanil, and trimethoprim) and 
the artemisinin compounds (artemisinin, dihydroartemisinin, artesunate, arteether, and 
artemether). 
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Artemisinins which are today the most effective antimalarial drugs are the oldest which 
have been in use. Artemisinins are the active ingredient in extracts of the plant qinghaosu 
(Artemisia annua) which have been used in traditional medical practice in China for over 
two millennia. The rediscovery of the artemisinins in the early 1970s constituted the best 
development in the treatment of multi-drug resistant malaria (Hien and White, 1993; 
Haynes, 2001). These drugs are structurally unrelated to existing antimalarial drugs. They 
are rapidly effective, safe, with no known clinical resistance and with the broadest time 
window of antimalarial effect (from ring forms to early schizonts and even gametocytes). 
The artemisinins act faster than any other antimalarial drug, with an approximate parasite- 
and fever-clearance time of 32 hours, in constrast to 2-3 days needed with conventional 
antimalarial drugs to resolve symptoms (Price, 2000). The essential pharmacophore is 
structurally and mechanistically unique: an endoperoxide bridge that undergoes iron-
catalysed activation to form toxic free radicals. Recent studies indicate that artemisinins 
inhibit ATPase and alter intracellular calcium stores (Eckstein-Ludwig et al., 2003). One 
liability of the artemisinins is the recrudescence of fully sensitive parasites upon 
monotherapy due to their short half life. The current recommended use of artemisinins is in 
combination therapy (WHO, 2001), where they effect a rapid and massive decrease in 
parasite burden and their gametocidal activity may lessen transmission of resistant 
parasites to the mosquito. Artemisinin and its derivatives (artemether and artesunate) are 
being used in combination with other antimalarial drugs for treatment of uncomplicated 
malaria, and as parenteral or rectal formulations for severe disease.  
Quinoline antimalarials and related alcohols owe their origins to quinine – an active 
ingredient of Cinchona bark – and as such share obvious structural anology. They 
constitute the largest class of antimalarials with chloroquine being the pre-eminent agent in 
the class. Chloroquine and other 4-substituted quinolones kill malaria parasites by 
interfering with the detoxification of haem by effectively blocking the sequestration of 
toxic heme into hemozoin within the food vacuole (Sullivan et al., 1996). Chloroquine 
accumulates in parasitized red cells, particularly in the acidic digestive food vacuole, to 
reach levels hundreds of times those in plasma, and the accumulation is reduced 
substantially in chloroquine-resistant cells (Macomber et al., 1966). Chloroquine resistance 
has been correlated with mutations in a transporter found on the food vacuole membrane 
(chloroquine resistance transporter, CRT). Another food vacuole transporter gene, multi-
drug resistance gene 1 (MDR1), has been implicated to play an ancillary role in resistance.  
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     Chloroquine                                         Amodiaquine                                           Piperaquine 
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Figure 5:  Structures of selected antimalarial drugs.  
4-amino quinolines (chloroquine and amodiaquine), quinoline alcohols (mefloquine and 
quinine), bisquinoline (piperaquine) and 8-amino quinolines (primaquine) interfere with 
heme polymerization. Pyrimethamine, sulfadoxine, and cycloguanil are substrate analogs 
that interfere with folate metabolism. Proguanil is converted in humans to cycloguanil by 
cytochrome oxidase. Newer antimalarials with novel structures and mechanisms include 
atovaquone and the artemisinins. 
 
Relatively small changes in the quinoline structure can enhance compound uptake into the 
food vacuole of chloroquine-resistant parasites (Ridley and Hudson, 1998). Resistance to 
quinine, mefloquine and halofantrine is probable because of mechanisms similar to those 
observed for chloroquine. Unlike chloroquine, however, these compounds do not currently 
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face high levels of resistance, and they thus remain, depending on the region, completely 
or partly active. The major disadvantage of the 8-amino quinolines like primaquine is the 
induction of haemolytic anemia in subjects with glucose 6-phosphate dehydrogenase 
(G6PD) deficiency as a potentially life-threatening adverse effect. This is likely related to 
their ability to generate ROI and the decreased reducing potential of G6PD-deficient 
erythrocytes. 
Another important group of antimalarials constitute the antifolates which exploit the fact 
that folate biosynthesis in malaria parasites is distinctly different from that in other 
systems. Tetrahydrofolate is an essential cofactor in the methyl transfer reactions that 
generate monomers for protein and nucleic acid synthesis. Two kinds of antifolates exist; 
the first type consisting of drugs like pyrimethamine and proguanil inhibit the enzyme 
dihydrofolate reductase while the second type of antifolates consisting of sulfonamides like 
sulfadoxine and dapsone inhibit the dihydropteroate synthetase. The application of 
antifolates in antimalarial chemotherapy was greatly enhanced by the discovery of an 
extraordinary degree of synergism in drug combinations involving both classes of 
antifolates which is suspiciously linked to multiple blockades in a dihydrofolate metabolic 
pathway (Wang et al., 2004). The molecular basis for resistance to antifolates, such as 
sulfadoxine-pyrimethamine has been well characterized. P. falciparum resistance to 
sulfadoxine-pyrimethamine is primarily conferred by successive single-point mutations in 
parasite genes that encode the target enzymes dihydrofolate reductase and dihydropteroate 
synthetase.  
Atovaquone, a hydroxynaphthoquinone derivative, is an analog of ubiquinone, a parasite 
mitochondrial electron-carrier which is the cofactor of the dihydroorotate dehydrogenase. 
Atovaquone acts by inhibiting parasite mitochondrial electron-transport (Robert et al., 
2001). The best application of atovaquone for treatment is in a synergistic combination of 
atovaquone with proguanil (an antifolate) as Malarone® whereby the combination is well 
tolerated and more effective than CQ alone, CQ-sulfadoxine/pyrimethamine, or 
mefloquine, against acute uncomplicated multidrug resistant P. falciparum. It is also 
effective in regions where proguanil alone is ineffective due to resistance. The combination 
however, is expensive and not easily affordable in most African countries. 
Antibiotics like tetracycline, doxycycline, and clindamycin targeting prokaryotic 
translation have antimalarial action through the inhibition of prokaryote-like protein 
synthesis in the apicoplast. The action of these antibiotics is slow, so they are being used 
increasingly in combination with other antibiotics to augment their activity (WHO, 2001). 
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Factors involved in the decision on the best treatment for malaria include the parasite 
species, the severity of disease, the patient's age and immune status, the parasite's 
susceptibility to the drugs (i.e. drug resistance), and the cost and availability of drugs. Drug 
resistance, and in particular chloroquine resistance, is a major public health problem in the 
control of malaria. Major factors involved in the development of drug resistance are shown 
below (Table 1). Cross-resistance between antimalarials is a phenomenon linked to the 
common or shared aspects of their modes of action and probably of their resistance 
mechanisms. A correlation analysis is the first indication of a common mode of action and 
perhaps a common mechanism of resistance (Le Bras and Durand, 2003). 
 
Table 1:       Factors contributing to development and spread of drug resistance 
 
Factor Comments 
Self-treatment Individuals may only take the drug until symptoms clear or will 
take lower doses to save money.  
Poor compliance Individuals may not complete the full course of treatment because 
of drug side effects.  
Mass administration The widespread use of a drug in an area of intense transmission 
increases drug pressure by exposing a larger parasite population to 
the drug. 
Long drug half-life Drugs that are slowly eliminated will lead to a longer exposure of 
the parasite to subtherapeutic drug concentrations.  
Transmission intensity High levels of transmission may allow re-infection while drugs are 
at sub-therapeutic levels.   
Adapted after www.tulane.edu/~wiser/protozoology/notes/malaria.html#treat 
 
 
1.1.5.3 Control through vaccines 
Vaccines have been shown to be one of medicine’s most cost-effective interventions as 
they induce an immune response in the infected host resulting in a marked decrease of the 
incidence of the disease which progressively leads to the eradication of the disease. The 
discovery and implementation of a safe and effective vaccine against malaria is a major 
priority in the control of the disease (Tongren et al., 2004). However, an effective vaccine 
for malaria still remains elusive. The acquisition of natural protective immunity against 
malaria by adults living in malaria endemic zones provides hope that a vaccine against 
malaria could be developed. The ability to tolerate high parasitaemias without apparent 
adverse effects relates to the development of “antitoxic” immunity (Playfair et al., 1990). 
The host adapts to repeated infection by producing less cytokines for a given quantum of 
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parasites (Riley et al., 1988). Unfortunately, the immune response that correlates with 
protection in these life long residents of endemic areas has not been identified, so 
development of a vaccine that mimics this immunity remains difficult. 
It may be possible to intervene at any or a combination of the stages in the parasite’s life 
cycle to produce an effective vaccine (Figure 6). Malaria vaccines could be directed against 
the sporozoite stage of the malaria parasite to prevent infection, or against the stages in 
human blood – the asexual stage to prevent clinical disease, or the sexual stage to prevent 
transmission.  
 
 
 
Figure 6:  Malaria life cycle and vaccine targets.  
CS = circumsporozoite; TRAP = thrombospondin-related adhesive protein; EXP-1 = 
exported antigen 1; LSA1 = liver stage antigen 1; MSP-1 = merozoite stage protein 1; 
GLURP = glutamate-rich protein; AMA-1 = apical membrane antigen 1; Pf = 
Plasmodium falciparum; Pv = P. vivax (adapted after Ballou et al., 2004). 
 
Much interest has been directed to pre-erythrocytic stage vaccines which are designed to 
prevent invasion of hepatocytes by sporozoites or to destroy infected hepatocytes (Kester 
et al., 2001). Blood stage vaccines to eliminate or reduce the number of blood stage 
parasites have mainly focused on antigens contributing to erythrocyte invasion (WHO, 
2004). Transmission-blocking vaccines are designed to prevent mosquitoes that feed on 
vaccinated individuals from becoming infected, reducing transmission and providing 
indirect protection to the entire population (Kaslow, 2002). However, four types of malaria 
vaccines namely synthetic peptide SPf66 and merozoite surface protein / ring-infected 
erythrocyte surface antigen MSP/RESA vaccines (against the asexual stages of the 
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Plasmodium parasite) and CS-NANP and RTS,S vaccines (against the sporozoite stages), 
have been tested in randomized controlled trials in endemic areas and have demonstrated 
varying levels of protective immunity. 
 
The development of malaria vaccines faces the following challenges. 
• The need to cope with diverse antigenic types 
• The importance of stimulating a life long response that is boosted by natural 
infection.  
 
Recent developments, including better methods for antigen production, improved 
adjuvants and novel delivery systems, provide optimism that sustained and appropriate 
long-lived immunity can be achieved (Brown and Reeder, 2002). 
 
1.2  Rationale of the study 
The difficulties that have been encountered in malarial vaccine development projects have 
indicated that the complete eradication of the disease malaria has to be the result of a 
synergistic combination of various malarial control measures as no single one can be 100% 
effective. Researchers, pharmaceutical companies, government policy makers, 
international bodies like WHO, local communities of endemic areas and the international 
community all have to combine their efforts in the eradication process. In this light, we – 
as malaria researchers searching for new drug alternatives against the parasite – developed 
three new projects in search of new alternative drugs as our own contribution in the fight 
against malaria. These projects involve the exploitation of the chemotherapeutic value of 
the glyoxalase detoxification system, selective inhibition of P. falciparum thioredoxin 
reductase (PfTrxR) which has been previously-validated as a drug target by gene-knockout 
experiments, and characterization of the in vitro antimalarial properties of methylene blue. 
An introduction to each of the above-mentioned projects as well as other related aspects is 
given below. 
 
1.2.1 The glyoxalase system 
The glyoxalase (Glo) system, a glutathione (GSH)-dependent detoxification system 
involved in the conversion of toxic 2-oxoaldehydes to the corresponding non-toxic 2-
hydroxyacids, is composed of two enzymes: glyoxalase I (GloI, EC 4.4.1.5) and glyoxalase 
II (GloII, EC 3.1.2.6). GloI converts the non-enzymatically produced hemithioacetal from 
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a 2-oxoaldehyde and GSH to a thiolester of GSH which can then be readily hydrolysed by 
GloII producing a 2-hydroxyacid and regenerating GSH (Figure 7; Martins et al., 2001). 
GloI is a member of the vicinal oxygen chelate metalloenzyme family (Armstrong, 2000), 
and contains a paired βαβββ motif providing a metal coordination environment. The 
reaction types catalyzed include isomerization (glyoxalase I containing Zn2+ and/or Ni2+), 
epimerization (methylmalonyl-CoA epimerase with Co2+), oxidative cleavage of C-C 
bonds (estradiol dioxygenase, Fe2+and/or Mn2+), and nucleophilic substitutions 
(fosfomycin resistance proteins, Mn2+, Mg2+). 
 
 
 
Figure 7:  Reactions of the glyoxalase system.  
GSH – glutathione, HTA – hemithioacetal, SDLGSH – S-D-lactoylglutathione (adapted 
from Martins et al., 2001). 
 
As revealed by sequence similarities and the X-ray crystal structure of human GloII, GloII 
is a member of the relatively newly defined metallohydrolase family containing the β-
lactamase fold consisting of a four-layered ß sandwich (Cameron et al., 1999b; Daiyasu et 
al., 2001). This superfamily also includes class B β-lactamase, arylsulfatase, mRNA 3’-
processing protein, a DNA cross-link repair enzyme, an alkylphosphonate uptake-related 
protein, CMP-N-acetylneuraminate hydroxylase, and insecticide hydrolases. 
Physiological substrates (2-oxoaldehydes) of the glyoxalase system are glyoxal formed in 
lipid peroxidation and glycation reactions, methylglyoxal arising from triose phosphates 
and thus glycolysis, ketone body metabolism and threonine catabolism, as well as 4,5-
dioxovalerate generated from 5-aminolevulinate and α-ketoglutarate (Figure 8). Previous 
studies have proven the electrophilic binding of 2-oxoaldehydes to guanyl residues of 
DNA and RNA as well as to lysyl, arginyl and cysteinyl residues of proteins (Lo et al., 
1994; Vaca et al., 1994). This leads to mutagenesis, apoptosis, protein cross-linking and 
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degradation, as well as to the synthesis and production of pro-inflammatory cytokines 
(Thornalley, 1996; Thornalley, 1998). 2-oxoaldehydes do mediate the formation of 
advanced glycation end products (AGEs) which can lead to pathophysiological 
complications in diabetes and are known to be cytostatic at low concentrations and 
cytotoxic at high concentrations (Thornalley, 1996; Thornalley, 1998).  
The glyoxalase system has been characterized in various organisms including man and 
other mammals (Marmstål et al., 1979; Biswas et al., 2002; Mearini et al., 2002), fish 
(Antognelli et al., 2003), higher plants (Crowder et al., 1997), yeast (Frickel et al., 2001), 
bacteria (Clugston and Honek, 2000), trypanosomes (Irsch and Krauth-Siegel, 2004), and 
nematodes (Sommer et al., 2001). The cytosol is the main cellular location of the Glo 
system; however some isoenzymes have been reported to contain signal targeting 
sequences for mitochondria and even plastids (Cordell et al., 2004). The ubiquitous 
distribution of the glyoxalase system, the presence of several isoenzymes in a single 
organism, and the high sequence similarity of Glo from different sources indicate the 
importance of the detoxification of 2-oxoaldehydes - produced from physiological 
reactions - in biological systems (Thornalley, 1993). 
Blood stages of the malarial parasite P. falciparum are mainly responsible for the clinical 
manifestations of the disease. After sequencing the P. falciparum genome, it is still unclear 
whether citric acid cycle and oxidative phosphorylation are significantly involved in 
energy production of the blood stages (Gardner et al., 2002). In any case, the parasite 
exhibits high glycolytic activity to cover energy demands resulting from its high 
proliferation rate (Jacobasch et al., 1990). This activity is indicated by an appr. 75 fold 
increase in glucose consumption in P. falciparum infected erythrocytes in comparison with 
normal erythrocytes (Sherman, 1979) and exposes the parasite to higher fluxes of 
methylglyoxal produced by the spontaneous decomposition of triose phosphates 
(glyceraldehyde-3-phosphate and dihydroacetone phosphate) during the triose phosphate 
isomerase reaction of glycolysis (Thornalley, 1996).  
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A. Formation of glyoxal 
 
B. Formation of methylglyoxal 
 
C. Formation of 4,5-dioxovalerate 
 
Figure 8:  Physiological formation of 2-oxoaldehydes. 
A). Glyoxal is formed by lipid peroxidation and by the slow oxidative degradation of 
glucose and glycated proteins. B). Methylglyoxal is formed by the non-enzymatic and 
enzymatic fragmentation of glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone 
phosphate (DHAP), acetone metabolism, and threonine catabolism. C). DOVA is formed 
by the oxidative degradation of 5-aminolevulinate and also by the reduction of α-
ketoglutarate (adapted after Thornalley, 1998). 
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The anti-malarial activity of Glo inhibitors was demonstrated by the growth inhibition 
caused by S-p-bromobenzylglutathione diethyl ester with IC50 values in the lower 
micromolar range (Thornalley et al., 1994). Selective inhibition of the Glo system leading 
to 2-oxoaldehyde stress within the parasite therefore provides a promising 
chemotherapeutic approach to the treatment of malaria. New chemotherapeutic approaches 
are urgently needed to fight against the increasing drug resistance of the parasite, to reduce 
the 2 million malaria deaths per year and the increased geographical spread of the disease 
(Olliaro, 2001; Greenwood and Mutabwinga, 2002). 
Recently, a glyoxalase I from P. falciparum (Iozef et al., 2003) was characterized. This 
cGloI belongs to a group of large glyoxalases I earlier characterized in yeast (Frickel et al., 
2001), later found in plants (Clugston et al., 1998), Plasmodium yoelii, and in insects such 
as Anopheles gambiae and Drosophila melanogaster (Iozef et al., 2003). Genes of these 
large glyoxalases have almost twice the size of the smaller glyoxalases of which human 
GloI is a good example. Amino acid sequences of the N- and C-terminal halves of their 
monomeric gene products are homologous to each other and to the two subunits of 
homodimeric small glyoxalases I (Ridderström and Mannervik, 1996a). These 
observations led to the gene duplication hypothesis on the evolution of these large 
glyoxalases, which was further supported by the fact that the recombinantly produced C-
terminal half of cGloI showed glyoxalase I activity (Iozef et al., 2003). In the homodimeric 
human Glo I, the active site is located at the dimer interface where side chains from both 
subunits interact with GSH and the metal ion which is zinc in most Glo I proteins and 
nickel in E. coli. 
The genes of a second putative GloI (GILP) as well as of two GloII (tGloII and cGloII) in 
P. falciparum have been identified.  This was followed by the comparative structural and 
functional analysis of the four putative glyoxalases with their isofunctional human 
counterparts within the frame of this thesis. First inhibitor studies serve as a basis for 
further elucidating the functions of the glyoxalase system in P. falciparum and for 
estimating its potential as target for the development of antimalarial drugs. 
 
1.2.1.1 Non-glyoxalase metabolism of methylglyoxal 
The ubiquitous glyoxalase system appears to act mainly against methylglyoxal toxicity. 
However, other enzymes have also been implicated in the detoxification of methylglyoxal 
and other 2-oxoaldehydes. 
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Aldehyde reductase or aldose reductase (EC 1.1.1.21) can catalyze the conversion of 
methylglyoxal to hydroxyacetone and lactaldehyde, using NADPH as cofactor. The 
product distribution is GSH-dependent. The non-enzymatic pre-equilibrium reaction 
between methylglyoxal and GSH to form the hemithioacetal in equilibrium with 
methylglyoxal (free and hydrated) provides two substrates for aldose reductase. 
Unhydrated methylglyoxal is converted to hydroxyacetone through reduction of the 
aldehyde functional group while the hemithioacetal is converted into lactaldehyde through 
reduction of the ketone functional group followed by dissociation of the resulting 
hemithioacetal (Vander Jagt and Hunsaker, 2003). The human placental enzyme has been 
well characterized. The KM and kcat value for methylglyoxal are 8 µM and 2.36 sec
-1, 
respectively (Vander Jagt et al., 1972). Lactaldehyde and hydroxyacetone could still be 
further reduced by aldose reductase to L- and D-propane-1,2-diol. A putative aldose 
reductase gene has been identified on the P. falciparum genome. The gene has been cloned 
into plasmid expression vectors but overexpression of the gene in E. coli and 
characterization of the gene product remain elusive (AG Becker-Brandenburg). 
Methylglyoxal reductase also catalyzes the conversion of methylglyoxal to L-lactaldehyde. 
Such activity has been found in mammalian liver homogenates of rat and goat as well as 
from yeast Saccharomyces cerevisiae and mould Aspergillus niger (Thornalley, 1993). The 
mammalian enzyme (89 kDa) requires NADH as cofactor and has broad substrate 
specificity for 2-oxoaldehydes and other aldehydes. The yeast enzyme (43 kDa) requires 
NADPH as cofactor, is specific for 2-oxoaldehydes and may be induced by exposure to 
methylglyoxal (Murata et al., 1986). 
Other methylglyoxal metabolising enzymes include betaine aldehyde dehydrogenase which 
is able to catalyze the NAD+-dependent oxidation of methylglyoxal to pyruvate, 2-
oxoaldehyde dehydrogenase catalyzing the NADP+-dependent oxidation to pyruvate, and 
pyruvate dehydrogenase which converts methylglyoxal to acetyl-CoA and formate 
(Izaguirre et al., 1998). Methylglyoxal is however a poor substrate for these enzymes. 
Methylglyoxal has been shown to be a slow competitive inhibitor for the oxidation of 
pyruvate as reported Ki values are in the lower millimolar range (Thornalley, 1993). 
Thus the various methylglyoxal metabolising pathways involve NADPH dependent 
reduction, glutathione dependent disproportionation and both NAD-dependent and NADP-
dependent oxidations. 
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1.2.2 The thioredoxin reductase system 
Plasmodium falciparum can not efficiently develop in glucose-6-phosphate dehydrogenase 
deficient erythrocytes and is sensitive to reactive oxygen species (ROS) resulting from the 
host immune system as well as from hemoglobin breakdown (Becker et al., 2004). The 
small amount of free heme escaping the various detoxification pathways, causes oxidative 
damage to host proteins and membranes, inhibits parasite enzymes and finally lyses 
erythrocytes. Two systems interact to protect malarial parasites against ROS: the 
glutathione system, comprising glutathione, glutathione reductase (GR), glutathione S-
transferase, and different glutaredoxin-like proteins and the thioredoxin system, 
comprising thioredoxin (Trx), thioredoxin reductase (TrxR), and thioredoxin dependent 
peroxidases (Becker et al., 2003; Becker et al., 2004, Rahlfs et al., 2002). Both systems are 
NADPH dependent.  
The redox-active small protein Trx is involved in ribonucleotide reduction and thus DNA 
synthesis as well as in the redox control of many cellular processes, including 
transcriptional control, protein folding, and enzyme regulation (Holmgren et al., 1998; 
Arnér and Holmgren, 2000). Trx is reduced by thioredoxin reductase (TrxR), a 
homodimeric FAD-dependent protein as indicated in the reaction below. 
 
 
NADPH     +    Trx(S)2   +   H
+             TrxR             NADP+   +   Trx(SH)2 
 
 
TrxR is found in nature in two forms. The low Mr form, with a subunit of 35 kDa, is 
present in prokaryotes and lower eukaryotes including yeast, and has one FAD and one 
redox active disulfide-dithiol in each monomer. The high Mr form, with a subunit of ca. 55 
kDa, contains one FAD and two redox active disulfide-dithiols per monomer and is found 
in higher eukaryotes including man and P. falciparum (Williams et al., 2000; Novoselov 
and Gladyshev, 2003). The second redox center in large TrxRs is located on a flexible C-
terminal arm of the protein. It picks up reducing equivalents from the N-terminal redox 
center of the other subunit and transfers them to Trx and other substrates. This second 
redox center is represented by a Cys-Sec pair in hTrxR. The accessibility and reactivity of 
this redox pair is presently exploited as target for chemotherapeutic agents – an approach 
that is supported by the fact that TrxR is found at ten-fold higher levels in many cancer cell 
lines than in normal cells (Kahlos et al., 2001; see Gromer et al., 2004, for review). In 
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PfTrxR the C-terminal redox pair is represented by a CysXXXXCys sequence. This 
difference in an essential structural and functional motif of host cell and parasite enzyme 
represents a most promising starting point for the development of specific PfTrxR 
inhibitors (Wang et al., 1999; Becker et al., 2000). The inhibition of PfTrxR is most likely 
to result in enhanced oxidative stress, to ineffective DNA synthesis and cell division, and 
to disturbed redox regulatory processes in the parasites. As demonstrated by knock out 
studies on P. falciparum, PfTrxR is essential for the parasite thus representing a validated 
drug target (Krnajski et al., 2002). 
The approach of our collaborative effort to develop a new generation of antimalarial drugs 
has been two-pronged. The first approach was based on a high throughput screen of 
350,000 compounds in the Pfizer library seeking compounds that discriminated between 
human and PfTrxR. The screen yielded 15 compounds 13 of which were Mannich bases, 4 
saturated and 9 unsaturated. A series of unsaturated mannich bases that act as mechanism 
based inhibitors (Davioud-Charvet et al., 2003) were synthesized. In the second approach, 
the subject of the present study, a series of inhibitors that act in the low micro- to 
nanomolar range and show high specificity for the P. falciparum enzyme have been 
developed. As described here, the inhibitors were evaluated on isolated P. falciparum and 
human TrxR as well as on P. falciparum in cell cultures. 
 
1.2.3 Methylene blue in antimalarial therapy 
Use of methylene blue (MB - a phenothiazonium salt, structure see scheme 1) in 
antimalarial therapy dates back to the 1890s when it became the first chemically 
synthesized drug to be employed in the treatment of malaria (Guttman and Ehrlich, 1891).  
 
Scheme 1: Structure of methylene blue 
 
Subsequently, chemical modification of chromophore and side chains of MB led to other 
antimalarials such as the 8-aminoquinolines and – via sontoquine – the 4-aminoquinolines 
(Figure 9).  
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Figure 9:  Chemical development of antimalarial drugs from methylene blue.  
The dialkylaminoalkylamino side chain equivalent to amodiaquine is shown in bold 
(Wainwright and Amaral, 2005). 
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Currently, the major indication for MB is the treatment of inherited and acquired 
methaemoglobinaemias due to its ability to reduce methaemoglobin (Mansouri and Lurie, 
1993; Coleman and Coleman, 1996). In addition, it is used as a neuroprotective agent in 
ifosfamide-based chemotherapy regimes. Since doses of the drug applied in 
methaemoglobinopathies have also been shown to have antimalarial effects and since MB 
was identified as a specific inhibitor of P. falciparum glutathione reductase, MB was 
reconsidered as useful antimalarial drug (Farber et al., 1998; Schirmer et al., 2003, Mandi 
et al., 2005). Further advantages of MB include its intrinsic inhibition of haem 
polymerization within the food vacuole (Atamna et al., 1996), its prevention of 
methaemoglobinaemia – a serious complication of malaria anaemia (Anstey et al., 1996) – 
and its relatively low price. Furthermore, MB shows high selectivity indices with respect to 
the viability of the human monocytic leukemia-derived cell line J-111 (Vennerstrom et al., 
1995; Atamna et al., 1996) indicating that its cytotoxicity for mammalian cells is low. 
Considerable side effects of MB have been reported (Goluboff and Wheaton, 1961; Peters, 
1970) but they are probably restricted to persons with certain forms of inherited G6PD-
deficiency. 
Malaria control has been greatly hampered by the continuous increase of parasite 
resistance to available anti-malarial drugs, chloroquine (CQ) – a highly effective and 
affordable drug – being the most prominent example (Le Bras and Durand, 2003; Arav-
Boger and Shapiro, 2005). Several drug combinations were formulated to prevent or delay 
resistance development (Ohrt et al., 2002; Yeung et al., 2004; Kremsner and Krishna, 
2004) and the use of CQ sensitizers in combination with CQ has been given high priority 
(Valecha et al., 1992). CQ-resistant parasites were shown to possess significantly 
increased concentrations of reduced glutathione (GSH) when compared with sensitive 
parasites (Dubois et al., 1995; Meierjohann et al., 2002; Ginsburg and Golenser, 2005). 
Thus, the reduction of glutathione disulfide by the flavoenzyme glutathione reductase (GR) 
as well as the de novo synthesis of GSH seem to be more efficient in resistant parasites. In 
Plasmodium, GSH is likely to be involved in buffering the reducing milieu, in antioxidant 
defense, redox signalling, DNA-synthesis, haem degradation, and in detoxification 
reactions catalysed by glutathione S-transferase (Ginsburg, 2003; Becker et al., 2003 & 
2004; Krauth-Siegel et al., 2005). Furthermore, the combination of CQ derivatives with the 
selective PfGR inhibitor 6-[2-(3-methyl)-naphthoquinolyl]hexanoic acid as double drug 
conjugate inhibited the growth of CQ-resistant P. falciparum both in vitro and in vivo 
(Davioud-Charvet et al., 2001). These and other observations suggest that the combination 
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of CQ with MB – as PfGR inhibitor and thus CQ sensitizer – might be useful. This 
approach has recently been tested in clinical trials in the Nouna District of Burkina Faso 
(Coulibaly et al., 2005; Mandi et al., 2005). In this study, cases of MB toxicity or 
intolerance were not reported, however, a clear advantage over a CQ monotherapy could 
not be observed, either (Meissner et al., 2005). Several reasons were proposed to be 
responsible for this clinical failure. They include (i) the possibility that the dosage of the 
highly water soluble MB was not high enough (Meissner et al., 2005), (ii) the possibility 
that MB and CQ do act antagonistically, and (iii) the possible formation of stable blue 
pigments in blood cells by MB leading to false positive counts of parasitaemia. 
In this work, the effects of MB on P. falciparum in cell culture including growth inhibitory 
effects on different parasite strains, stage specificity, uptake, and staining effects were 
systematically studied. In addition, the combination of MB with other clinically used 
antimalarials was tested in order to search for potential clinical drug combination therapies. 
 
1.2.4 Other aspects of the PhD project 
1.2.4.1 Glutathionylation of thioredoxin of P. falciparum 
Protein glutathionylation describes the formation of a disulfide bond between a cysteine 
residue in a protein and the cysteine in the tripeptide GSH (γ-glutamylcysteinylglycine). 
The modification can be induced in cells by oxidative stress as a protective mechanism to 
prevent the disruption of amino acid residues by reactive oxygen species (ROS). Such 
modification in P. falciparum is most likely to occur as the parasite shows high 
susceptibility to oxidative stress. Glutathionylation can occur by a direct oxidation of a 
protein and GSH, by thiol disulfide exchange between a protein and oxidized glutathione 
(GSSG), and also with the glutathione disulfide S-oxide (GS(O)SG) intermediate produced 
by decomposition of S-Nitrosoglutathione (GSNO, Li et al., 2001). Glutathionylation of 
proteins is reversible, as these proteins can be reduced by glutaredoxins (Holmgren, 1989), 
and the process serves to regulate protein functions depending on the GSH/GSSG ratio in 
the environment.  
Thioredoxin is a small (~ 12 kDa) ubiquitous redox protein with biological activities 
ranging from electron donor for ribonucleotide reductase, regulatory protein for NF-kB and 
ASK, to an extracellular cytokine. This study of the glutathionylation of P. falciparum 
thioredoxin (PfTrx) was triggered by the discovery of glutathionylation of certain cysteine 
residues on human Trx (Casagrande et al., 2002) under conditions of oxidative stress. 
PfTrx contains two cysteines at its conserved redox active site CGPC at positions 41 and 
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44, with an additional cysteine at position 54 of the recombinantly-synthesized histidine-
tagged protein. This study tries to investigate the susceptibility of PfTrx to the 
glutathionylation under conditions of oxidative stress. 
 
1.2.4.2 Lipoamide dehydrogenases of P. falciparum 
Lipoamide dehydrogenases (LipDH) belong to the homodimeric FAD-dependent cysteine-
oxidoreductase enzyme family which is mostly involved in the maintenance of redox 
balance and is considered as chemotherapeutic target for P. falciparum (Becker et al., 
2000). Members of this family catalyse the transfer of electrons between pyridine 
nucleotides and disulphides. LipDH constitutes part of the following enzyme complexes; 
pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain 2-oxo-acid 
dehydrogenase, as well as the glycine cleavage system in plants (Williams, 1992). The first 
two enzyme complexes are very important in the energy metabolism of the organisms in 
which they occur. The pyruvate dehydrogenase complex links glycolysis to the citric acid 
cycle and consists of pyruvate dehydrogenase (E1), lipoamide transacetylase (E2) and 
LipDH (E3). In these complexes, LipDH catalyzes the re-oxidation of protein-bound 
dihydrolipoyl residues transfering reducing equivalents to NAD+ via FAD (Scheme 2). 
 
       
        2 LipSH          +         LipDH·[FAD]              LipS2          +        LipDH·[FADH2] 
           Dihydrolipoic acid                                                            Lipoic acid                                 
           (reduced)                                                                       (oxidized) 
 
 
 
                            FADH2      +      NAD
+                          FAD        +     NADH       +     H+ 
 
 
Scheme 2: The lipoamide dehydrogenase reaction 
 
Glucose consumption in P. falciparum infected erythrocytes increases ~100 fold in 
comparison to normal erythrocytes. This renders the enzymes involved in glucose 
metabolism within the parasite attractive drug targets. Inhibition of P. falciparum LipDH 
(PfLipDH) should have inhibition effects on the pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase complexes. With the identification of two putative PfLipDH 
genes on chromosome 8 and 12, we set out to functionally characterize their recombinant 
gene products as well as investigate their potential as drug targets for P. falciparum. The 
inhibitory/stimulatory effect of MB on PfLipDH was also investigated. 
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1.3 Objectives of the study 
With the overall goal to contribute to the fight against drug resistant malaria through the rational 
design of new drugs and prevention of resistance development to artemisinin, the thesis aimed at 
exploring the chemotherapeutic value of the glyoxalase detoxification system, selective inhibition 
of P. falciparum thioredoxin reductase (PfTrxR), and the antimalarial properties of methylene blue. 
In order to do this, the following objectives with respect to each project were drawn. 
 
1.3.1 The glyoxalase system 
 
• Cloning, overexpression and purification of the recombinant Glos of P. falciparum. 
• Biochemical and kinetic characterization of Glos of P. falciparum.  
• Analysis of the effects as well as the mode of action of Glo inhibitors on Glos of P. 
falciparum in a search for selectivity. 
• Analysis of the effects of Glo inhibitors on cultures of P. falciparum. 
• Development of X-ray-diffractable crystals – and as such structures – of Glo 
enzymes which could facilitate the design of selective inhibitors of Glos of P. 
falciparum. 
• Development of model structures of Glo enzymes of P. falciparum based on X-ray 
structures of human Glos. 
 
1.3.2 The thioredoxin reductase of P. falciparum 
 
• Study of the mechanism of inhibition of some selective inhibitors of PfTrxR. 
• Analysis of the effects of these inhibitors on cultures of P. falciparum. 
• Analysis of the effects of drug combination of these inhibitors with CQ, MB and 
artemisinin. 
 
1.3.3 Methylene blue in antimalarial chemotherapy 
 
• Study of the susceptibility of P. falciparum parasites to MB. 
• Determination of the P. falciparum growth stage-specificity of MB. 
• Analysis of the parasitic uptake of MB. 
• Analysis of the drug combination effects of MB with clinically-used antimalarials. 
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2 Materials and methods 
2.1 Materials 
Most of the reagents used were obtained at their highest purity from Roth, Merck or 
Sigma. 
2.1.1 Chemicals 
Acrylamide solution     BioRad, München 
Ammonium persulphate    Merck, Darmstadt 
Ampicillin      Sigma, Steinheim 
Bacto-Agar      Roth, Karlsruhe 
Bovine serum albumin    Roth, Karlsruhe 
Chloramphenicol     Roth, Karlsruhe 
Ethidium bromide     Sigma, Steinheim 
Ethylenediaminetetraacetate (EDTA)  Roth, Karlsruhe 
Gentamycin      Gibco, Karlsruhe 
Glucose      Merck, Darmstadt 
Glycerin      Roth, Karlsruhe 
Hypoxanthine      Sigma, Steinheim 
Isopropylthiogalactoside (IPTG)   Roth, Karlsruhe 
Kanamycin      Roth, Karlsruhe 
Lipid rich bovine serum albumin (Albumax) Gibco, Karlsruhe 
Mercaptoethanol     Sigma, Steinheim 
Milk powder      Biorad, München 
Pepstatin      Sigma, Steinheim 
Phenylmethylsulfonylfluoride (PMSF)  Sigma, Steinheim 
RNase I      Roth, Karlsruhe 
Saponin      Roth, Karlsruhe 
Sodium dodecyl sulphate (SDS)   Merck, Darmstadt 
Sorbitol      Roth, Karlsruhe 
Taq polymerase reaction buffer (10x)  Fermentas, St. Leon-Rot 
Tris       Roth, Karlsruhe 
Trypton      Roth, Karlsruhe 
Tween-20      Merck, Darmstadt 
Yeast Extract       Roth, Karlsruhe 
 
2.1.2 Malaria drugs 
Mefloquine      Roche, Mannheim 
Artemisinin      Aldrich, Steinheim 
Chloroquine      Sigma, Steinheim 
Primaquine      Aldrich Chem Co, Milwaukee; USA 
Pyrimethamine     Sigma, Steinheim 
Quinine      Acrös Organics, Geel; Belgium 
Amodiaquine      Sigma, Steinheim 
Methylene Blue     Roth, Karlsruhe 
 
2.1.3 Enzymes 
DNase I      Roche, Mannheim 
Pfu polymerase     Promega, Mannheim 
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Restriction Enzymes     MBI Fermentas, St. Leon-Rot 
Taq polymerase     MBI Fermentas, St. Leon-Rot 
 
2.1.4 Antibodies 
Mouse anti-glutathione antibodies   Virogen, USA 
Rabbi anti-mouse immunoglobulins   DAKO A/S, Denmark 
Mouse anti-histidine tag IgGs   Qiagen, Hilden 
   
2.1.5 Kits 
Bradford kit      Biorad, München 
Crytallization kit (crystal screen 1&2)  Hampton Research, Laguna Niguel, 
U.S.A 
Plasmid extraction kit    Qiagen, Hilden 
QIAquick gel extraction kit    Qiagen, Hilden 
QIAquick PCR-purification kit   Qiagen, Hilden 
Ready-To-Go ligase     Amersham, Freiburg 
Western lightning chemiluminescence reagent   Perkin Elmer, Boston, U.S.A. 
 
2.1.6 Instruments 
Accurate scale     Scaltec Instruments, Göttingen 
Beckmann spectrophotometer DU® 650  Beckman, München 
Biophotometer     Eppendorf, Hamburg 
Bosch PE626 normal scale    Gebr. Bosch, Jungingen 
Gel set up (agarose gel)    Peqlab 
Hitachi spectrophotometer U-2001   Hitachi Ltd, Tokyo 
Incubator shaker     Thermo Life Sciences, Egelsbach 
LKB multiphor II nova blot    Pharmacia Biotech, Erlangen  
Megafuge 1.0 R     Heraus Instruments, Hanau 
Microscope axiostar     Zeiss, Jena 
Mini-Spin table centrifuge    Eppendorf, Hamburg 
OptimaTM TLX ultracentrifuge   Beckman, München 
PCR –normal and –gradient cyclers   Eppendorf, Hamburg 
pH-Meter (Φ 350 pH/Temp/mV Meter)  Beckman, München 
Quarz cuvettes     Hellma, Müllheim 
Salvant, SpeedVac, vacuum centrifuge  Thermo Life Sciences, Egelsbach 
Sonicator      Bandelin Electronics, Berlin 
Sorvall centrifuge RC5C    Du Pont Company, Wilmington 
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2.1.7 Biological materials 
2.1.7.1 cDNA libraries and erythrocytes 
P. falciparum cDNA libraries: cDNA banks from blood stages of the P. falciparum 3D7 
strain were kindly provided by Prof. David Kaslow (National Institute of Health, Bethesda, 
USA) and were used as templates for the amplification of all P. falciparum glyoxalase 
genes. 
Human lung cDNA library was kindly provided by Dr. Lutz Schomburg (Charité, Berlin, 
Germany) and used for the amplification of the human glyoxalase I gene. 
Clones of the human glyoxalase II gene in the pKK-D vector were kindly provided by 
Prof. Bengt Mannervik (Biomedical Center, Uppsala, Sweden) 
Human erythrocytes were obtained from the Red Cross, Frankfurt. 
 
2.1.7.2 Plasmids 
 
Plasmid 
Antibiotic Resistance, 
other importance 
Source 
pQE 30 Ampicillin Qiagen, Hilden 
pKK-D Ampicillin Gift from Professor Mannervik 
(Uppsala, Sweden) 
pREP Kanamycin, lac repressor gene Qiagen, Hilden 
pRIG  
 
Chloramphenicol, tRNAs for R, I and G Gift from Professor Wim Hol (Baca 
& Hol, 2000) 
pRARE Chloramphenicol Novagen, Darmstadt 
 
 
2.1.7.3 Escherichia coli cells 
 
E. coli strain Genotype Reference / Manufacturer 
XL1-Blue recA1, endA1, gyrA96, thi-1, hsd-r17, 
supE44, relA1, lac, [F' pro AB, 
laclqZ∆M15, Tn10, (Tetr)] 
(Bullock et al., 1987) 
Stratagene, LaJolla, USA 
M15 [pREP4] nalS, StrS, rifS, KmR, lac -, ara -, gal -, mtl -, 
F -, recA +, uvr + 
(Villarejo and Zabin, 1974) 
Qiagen, Hilden 
BL21 F- ompT hsdSB(rB
-mB
-) gal dcm (Wood, 1966) 
Stratagene, LaJolla, USA 
JRG LipDH deficient AG Prof. Krauth-Siegel, 
Heidelberg 
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2.1.7.4             Strains of P. falciparum 
 
Strain Origin Source 
K1 (Chloroquine-resistant) South-East Asia AG Prof. Lanzer, Heidelberg 
Dd2 (Chloroquine-resistant) Indochina AG Prof. Lanzer, Heidelberg 
HB3 (Chloroquine-sensitive) Honduras AG Prof. Lanzer, Heidelberg 
3D7 (Chloroquine-sensitive) The Netherlands AG Prof. Lanzer, Heidelberg 
 
 
2.1.8 Buffers and solutions 
 
2.1.8.1 Solutions for DNA electrophoresis 
10 x TBE:   1 M   Tris 
    1 M   Boric acid 
    20 mM  EDTA 
    pH 8.0 with acetic acid 
 
DNA Sample buffer  0.1%   Bromophenol blue 
    1 mM   Tris 
    60%   Saccharose 
    pH 8.3 with HCl 
 
 
2.1.8.2 Solutions for protein electrophoresis 
 
Sample buffer 
    62.5 mM Tris-HCL 
    25%  Glycerin 
    2%  SDS 
    0.01%  Bromophenol blue 
    5%  Mercaptoethanol 
 
Running buffer 
    1.5 M  Tris-HCl pH 8.8 
Stacking buffer 
    0.5 M  Tris   pH 6.8 
Electrophoresis buffer 
    25 mM  Tris 
    192 mM Glycin 
    0.1%  SDS 
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Coomassie staining solution 
 0.5%   Coomassie brillant blue R250 
    10%  Acetic acid 
    30%  2-Propanol 
 
Coomassie destaining solution 
    10%  Acetic acid 
    40%  Methanol 
 
 
 
2.1.8.3 Solutions for western blotting 
 
Anode buffer I    
300 mM  Tris 
 
Anode buffer II      
25 mM  Tris 
 
Cathode buffer       
40 mM  6–Aminohexanic acid 
 
TBS buffer       
10 mM  Tris 
     155 mM  NaCl 
     pH 8.0 with HCl 
 
TBST buffer      
0.05%  Tween 20 
     ad 1000 ml with TBS Buffer  
 
Blocking buffer    5% milk powder in TBS Buffer 
 
Ponceau staining solution    
1%   Ponceau S 
     1%  Acetic acid 
Ponceau destaining solution 
     1%   Acetic acid 
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2.1.8.4 Extraction of parasites from infected red blood cells 
 
Saponin lysis Buffer     
0,02 % (w/v)  Saponin 
   in:   7 mM  K2HPO4   
      1 mM  NaH2PO4  
             11 mM  NaHCO3  
            58 mM  KCl  
            56 mM  NaCl  
                1 mM  MgCl2  
             14 mM  Glucose,   
pH 7.4 with HCl  
 
 
2.1.9 Growth medium 
LB medium   10 g   Tryptone 
      5 g  Yeast extract 
    10 g   NaCl 
    per litre of H2O 
 
ZY medium   20 g   Tryptone 
    15 g  Yeast extract 
      5 g  NaCl 
    per litre of H2O 
 
2 x YT medium  16 g  Tryptone 
    10 g  Yeast extract 
      5 g  NaCl 
    per litre of H2O 
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3 Methods 
3.1 Gene identification 
Complete open reading frames of two putative GloI genes on chromosome 6 and 
chromosome 11, two putative GloII genes on chromosome 4 and chromosome 12, and two 
PfLipDH genes on chromosome 12 (PfLipDH1) and chromosome 8 (PfLipDH2) were 
identified by online screening of the P. falciparum genome project 
(www.ncbi.nlm.nih.gov/Malaria/plasmodium-blcus.html) using other well known 
glyoxalases and LipDH as search strategies. 
 
3.2 Polymerase chain reaction (PCR) 
The PCR is an in vitro procedure for synthesizing enzymatically, specific sequences of 
DNA (Mullis and Faloona, 1987). Two oligonucleotide primers that flank the DNA region 
of interest and hybridise to opposite strands of the DNA are utilised in this technique. A 
series of repetitive cycles involving template denaturation, primer annealing and the 
extension of the annealed primers using the thermostable Taq DNA polymerase 
accomplishes the DNA amplification. At the completion of the reaction, amplification 
products are analyzed by size fractionation using agarose gel electrophoresis and then 
purified with a QIAquick PCR purification kit. 
Conditions under which a PCR is carried out varies depending mainly on the specific DNA 
sequence to be amplified and the oligonucleotide primers which are to be used for the 
amplification. Detailed descriptions of the conditions under which the Glo and LipDH 
genes investigated in this study were amplified are shown in Tables 2 and 4, respectively. 
For the P. falciparum glyoxalase and LipDH genes, N-terminal and C-terminal primers 
were designed from the sequence of the 5' and 3' ends of the genes, respectively. A P. 
falciparum gametocyte cDNA library from the strain 3D7 was used as template for the 
PCR amplification. 
Primers used for the amplification of the human GloI gene were designed from the gene 
sequence obtained from the GenBankTM/EMBL Data Bank (Acc. No. NP_006699). 
Primers were designed such that the 5' and 3' ends of the genes to be amplified would be 
flanked by additional DNA containing restriction sites necessary for subsequent cloning of 
the genes into plasmid vectors. A human lung cDNA library was kindly provided by Dr. 
Lutz Schomburg (Charité, Berlin) and used as a template. Amplification of the human 
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GloII gene was unnecessary as a clone of the gene present in pKK-D vector was provided 
by Professor Mannervik (Uppsala, Sweden). 
 
3.3 Cloning and overexpression of genes 
All the enzymes used in this study were synthesized by plasmid-directed expression in E. 
coli. Plasmids carrying resistance genes to particular antibiotics were used as vectors so 
that treatment with antibiotics could be used as an indicator of plasmid/vector maintenance 
in E. coli cultures. Appropriate restriction enzymes were used to cut both the flanking ends 
of the amplified genes (to make them sticky) and the plasmid vector. Amplified genes cut 
with particular restriction enzymes could then be introduced into the multiple cloning site 
of a plasmid vector which had been cut with the same restriction enzymes. The sticky ends 
of both the gene and the vector then anneal to each other by complementary base pairing 
since they were generated by the same restriction enzyme. The gene was then ligated into 
the vector by the use of a ligation kit which exploits the action of DNA ligase. All products 
were verified by DNA sequencing. The generated recombinant plasmid was then used to 
transform the appropriate competent E. coli by heat shock treatment. The transformed E. 
coli were then grown in the most suitable growth medium and IPTG induction of the 
expression of the recombinant genes was carried out at optimized levels during the growth 
of the E. coli. 
All glyoxalase genes were cloned into the expression vector pQE30 and overexpressed in 
E. coli cells. The human GloI gene was also cloned into pQE30 and overexpressed using E. 
coli BL21(DE3) plus S cells. The gene encoding cytosolic human GloII in the vector pKK-
D (Ridderström et al., 1996) was overexpressed in E. coli JM109. Table 2 delineates gene 
cloning and overexpression procedures of the various human and P. falciparum glyoxalase 
genes that were used in this study.  
Genes of PfLipDH1 and PfLipDH2 were either cloned into the pQE30 or pRSET(A) 
expression vector and the overexpression was optimized in several different E. coli strains. 
The pRIG was employed in all of the overexpressions in order to adapt the codon usage of 
the E. coli expression to that of P. falciparum. 
PfTrxR and PfTrx were prepared as described in Kanzok et al. (2000).  
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3.4 Site-directed mutagenesis 
The Tyr185Phe mutant of cGloII was generated by site directed mutagenesis using 
standard PCR with Pfu DNA polymerase using the following primers: OPfG4Ys 5' GCG 
GAC ATG AGT TTA CCC TTA ATA ATT TAA GG 3' and OPfG4Yas 5' CCT TAA 
ATT ATT AAG GGT AAA CTC ATG TCC GC 3'. The expression clone of cGloII was 
used as a template. The resulting PCR product was sequenced to make sure that no 
unwanted mutations had been introduced. 
 
3.5 Purification of glyoxalase enzymes 
After recombinant production, the E. coli cells were harvested and resuspended in their 
various lysis buffers containing lysozyme and DNase and supplemented with PMSF, 
cystatin and pepstatin as protease inhibitors. The cells were broken by ultrasonic treatment, 
extracts centrifuged at 17000 rpm for 30 minutes and all proteins of interest (glyoxalases) 
were purified to homogeneity from the supernatants using S-hexylglutathione and Ni-NTA 
affinity matrices. S-hexylglutathione sepharose columns are widely used in the purification 
of glutathione-related enzymes such as glyoxalases, GSTs, and thiol transferases. Table 3 
indicates the purification procedure used for particular proteins as well as the yield 
obtained per litre of overexpression medium. Purity and concentration of purified proteins 
were determined by Coomassie blue staining after SDS–PAGE and the Bradford assay 
(Bio-Rad) or A280 method. 
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Overexpression 
Overnight  at 30°C after induction 
with 0.25 mM IPTG at OD600 = 0.3 
using LB medium containing 8 mM 
MgSO4, 1 mM ZnSO4 and 10 mM 
Tris, pH 7.5 
Overnight at 24 – 30°C after 
induction with 0.25 mM IPTG at 
OD600 = 0.7 – 0.8 using LB medium 
containing 8 mM MgSO4 and  10 
mM Tris, pH 7.5 
6 hours at 37°C after induction with 
1 mM IPTG at OD600 = 0.7 using  
LB medium containing 8 mM 
MgSO4 and 10 mM Tris, pH 7.5  
 
 
 4 hours at 37°C after induction with 
1 mM IPTG at OD600 = 0.5 using  
LB medium 
Overnight at 30°C after induction 
with 0.25 mM IPTG at OD600 = 0.3 
using ZY medium containing 1 mM 
ZnSO4 
Overnight at 37°C after induction 
with 0.25 mM IPTG at OD600 = 0.3 
using ZY medium 
E. coli 
strain 
M15 
M15 
BL21 
M15 
XL-I Blue 
BL21 
(DE3) 
JM109 
Expression 
vector 
pQE30 
pQE30 
pQE30 
pQE30 
pQE30 
pKKD 
PCR 
Iozef et al., 2003 
94°C, 30´´ 
65°C, 45´´  
72°C, 60´´  
25 cycles 
94°C, 30´´  
50°C, 45´´  
72°C, 90´´  
35 cycles 
94°C, 30´´  
60°C, 30´´  
72°C, 90´´ 
35 cycles 
94°C, 30´´  
64°C, 30´´ 
72°C, 45´´  
35 cycles 
Ridderström et al., 1996  
Restriction site 
Iozef et al., 2003 
BamHI 
 
 
HindIII 
BamHI 
 
HindIII 
BamHI 
 
 
SacI 
BamHI 
 
 
HindIII 
Ridderström et al., 1996  
Primer Sequence 
1. Sense 
2. Antisense 
       Iozef et al., 2003  
1. CGCGGGATCCAAACTTT
TTGTAGTCGTTATATTT
GTTC 
 
2. GCGCAAGCTTTTATTTG
TCTTTTAAGTAAACATT
ATATCCG 
1. CGCGGGATCCGCACAA
GAAATATCAAATTTAG 
 
2. GCGCAAGCTTTTATGAG
GCTTTAAAATTATCC 
 
1. CGCGGGATCCAAGCCAT
GCGCACAAGTACTTGTA
GTGC 
 
2. CGCGGAGCTCTTAAAAA
TTATTTTTTAATTGTCTT
AATTTAT 
1. CGCGGGATCCAAGCCAT
GCGCACAAGTACTTGTA
GTGC 
 
2. CGCGAAGCTTCTACATT
AAGGTTGCCATTTTG 
        Ridderström et al., 1996 
Gene / 
Accession 
numbers 
 cGloI 
AF486284 
 GILP 
  NP_703709 
 tGloII 
AF486285 
 cGloII 
AY494055 
 human GloI 
 NP_006699 
 human GloII 
 CAA62483 
 
 
Table 2:  Cloning and overexpression of human and P. falciparum glyoxalase genes. Restriction endonuclease sites added to 
the primer sequences are underlined 
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Table 3:  Purification of P. falciparum and human glyoxalases 
 
 
Enzyme First Purification Second Purification Yield/l 
culture 
cGloI S-hexylglutathione column in 10 mM Tris-HCl, 
pH 7.8; elution with 5 mM S-hexylglutathione 
Ni-NTA column; elution with 
100-200 mM imidazol                                           
3 mg 
GILP Ni-NTA column; elution with 50-75 mM 
imidazol                                         
Not necessary   5 mg 
tGloII S-hexylglutathione column in 10 mM Tris, pH 
7.8; elution with 3 M NaCl  
Ni-NTA column; elution with       
50 mM imidazol                                            
0.2 mg 
cGloII Ni-NTA column; elution with 30-200 mM 
imidazol                                
Not necessary   5 mg 
human GloI S-hexylglutathione column in 10 mM Tris-HCl, 
pH 7.8; elution with 5 mM S-hexylglutathione 
Ni-NTA column; elution with     
30-50 mM imidazol                                            
0.5 mg 
human GloII S-hexylglutathione column in 10 mM MOPS, pH 
7.2; elution with 3 M NaCl 
Not necessary   2 mg 
Washing steps on Ni-NTA columns were carried out with 50 mM sodium phosphate buffer, pH 8.0 containing 
300 mM NaCl. Imidazol concentrations used during elution were diluted in the same buffer. Washing and 
elution steps of all GloIs on S-hexylglutathione columns contained 200 mM NaCl. 
 
 
Table 4:  Optimization of the expression conditions for PfLipDH1 and PfLipDH2 
 
 
Gene Expression Vector and        
E. coli strain 
Protein yield after 
purification 
pQE PfLipDH1 in M15 
cells plus pRIG 
PfLipDH1 obtained 
with about 30% purity 
pQE PfLipDH1 in XL1 
Blue / Nova Blue cells 
plus pRIG 
Large amounts of 
PfLipDH1 obtained in 
inclusion bodies 
pQE PfLipDH1 in JRG 
1342 cells plus pRIG 
No PfLipDH1 obtained 
pQE PfLipDH1 in BL21 
cells plus pRIG 
No PfLipDH1 obtained 
PfLipDH1 
Forward primer 
CGCGGAGCTCAACAGCGT 
TATTTTTAGAGCAC  
Reverse primer 
GCGCAAGCTTTTACATGT 
GTATAGGTTTATCAAAAG 
PCR 
94°C, 30´´ 
57°C, 30´´  
72°C, 90´´  
   35 cycles 
pRSETPfLipDH1 in M15 
cells plus pRIG 
No PfLipDH1 obtained 
pQE PfLipDH2 in M15 
cells plus pRIG 
No PfLipDH2 obtained PfLipDH2 
PCR conditions (AG Becker-
Brandenburg) 
pQE PfLipDH2 in XL1 
Blue cells plus pRIG 
No PfLipDH2 obtained 
In all the above-stated overexpression systems, the following parameters were varied; time allowed for 
overexpression (from 4 hours to overnight overexpressions), overexpression temperature (from 25°C to 
37°C), and amount of IPTG used for induction of gene expression (from 0.2 mM to 1 mM).  
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3.6 SDS-PAGE 
The discontinuous buffer system for running SDS-PAGE was performed according to 
Laemmli (1970). This method separates denatured and reduced proteins according to their 
size and gives an indication of the purity of elution fractions after purification of proteins.  
The proteins are initially mixed in a volume ratio of 1:2 with sample buffer and heated at 
95°C for 5 minutes to denature the proteins. The proteins are then loaded into a pre-cast 
two-part polymerized acrylamide gel. The first part consists of a stacking gel (Tris-
Glycine-Buffer pH 6.8, 4% acrylamide/bisacrylamide, 1% SDS) into which the proteins 
are loaded. The second part consists of a separation gel (Tris-Glycine-Buffer pH 8.8, 10-
15% acrylamide/bisacrylamide, 1% SDS) on which the proteins are separated. 
Polymerization of the acrylamide in both the stacking and the separation gels is catalyzed 
by TEMED and initiated by APS. The amount of acrylamide/bisacrylamide on the gels 
influences the pore size and elasticity of the gel. The gels are run in an electrophoresis tank 
containing electrophoresis buffer at a voltage of 200V.  
After the separation process, the gel was either stained with Coomassie and further 
destained in Coomassie destaining solution or used directly for western blotting. 
 
3.7 Western blotting 
The semi-dry western blot method was performed according to Towbin et al. (1979). This 
method involves the transfer of proteins from gels into nitrocellulose membranes. It 
enables the immunological identification of proteins on nitrocellulose membranes by 
specific antibodies to the proteins e.g. the identification of a 6–histidine tag at the N-
termini of proteins by anti-histidine antibodies. 
Filter papers, gels and nitrocellulose membranes previously soaked in different appropriate 
buffers are aligned in between the graphite plates of the anode and cathode. The 
arrangement of the whole assembly is as follows: graphite cathode followed by 5 filter 
papers and the polyacrylamide gel soaked in cathode buffer, followed by the membrane 
and 2 filter papers soaked in anode buffer 2, followed by 3 filter papers soaked in anode 
buffer 1 and finally, the graphite anode. The transfer process is carried out at 0.8 mA/cm2 
of gel for 55 minutes. 
To view the efficiency of the transfer process, the nitrocellulose membrane is stained with 
Ponceau staining solution (for 30 seconds) and immediately de-stained with 1% acetic acid 
until the protein bands become invisible. Non-protein-bound sites on the membrane are 
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blocked by incubation of the membrane in TBS-buffer containing 5% milk powder 
overnight at 4°C or for 1 hour with gentle shaking at room temperature. Then the 
membrane is incubated in TBS-buffer containing a dilution of the primary antibody (e.g. 
mouse anti-histidine IgGs) overnight or for 1 hour with gentle shaking at room 
temperature. The primary antibody is washed off by two-times incubation in TBST for 10 
minutes followed by another wash in TBS for 10 minutes. The membrane is then incubated 
in a dilution of the secondary antibody (e.g. rabbit anti-mouse immunoglobulins) solution 
in TBS buffer. The secondary antibody should be able to recognize the primary antibody. 
After another washing step, immunostaining of the membrane is carried out with an 
enhanced chemiluminescence (ECL)-Kit in a dark room. The membrane is incubated with 
an equal mixture of detection solution 1 & 2, after which it is wrapped in a plastic foil and 
exposed to an X-ray film for periods of about 30 seconds to 10 minutes. The exposure time 
is dependent on the strength of the signals obtained. 
 
3.8 Concentration of proteins 
To increase the protein concentrations of pure protein solutions, the proteins were forced 
through centriprep and microcon columns (YM 3, 10, or 30 – Amicon, Beverly, USA) 
which contain membranes with pore sizes that do not allow flowthrough of the protein of 
interest. The process is carried out by centrifugation at 3700 rpm and 4°C until a desired 
volume or a minimal volume of 600 µl and 270 µl for the centriprep and microcon 
columns, respectively, is attained. The amount of protein in the concentrate is then 
measured. 
 
3.9 Determination of protein concentrations 
Two methods were employed. 
 
3.9.1 A280 method 
This method depends on the absorption of light by aromatic amino acid side chains of 
proteins such as tyrosin and tryptophan at 280 nm. The specific molar extinction 
coefficient ε is obtained through online tools (Justbio, ProtCalc; www.justbio.com) and by 
taking into account the absorption of specific prosthetic groups (e.g. FAD).  
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The protein concentration is calculated with the following formula. 
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whereby ε= molar extinction coefficient at λ of 280 nm, d= distance moved by the light in a cuvette = 1 cm  
 
3.9.2 Bradford method 
The Bradford method is based on the detection of a blue colouration that results after 
mixing a protein sample with Coomassie brilliant blue R-250. The blue colouration is 
proportional to the amount of protein in the sample. By determining the optical density 
(OD) at a wavelength of 595 nm and by extrapolation of this OD595 on a standard linear 
graph, the concentration of the protein can be determined. The standard linear graph is 
obtained by plotting known concentrations of BSA against their corresponding OD595s 
after treatment with the Coomassie reagent. The process is carried out according to the 
manufacturer’s (BIORAD) instructions. 
 
3.10   Enzymatic assays 
Enzyme activity is determined by measuring either the rate of disappearance of substrate or 
the rate of appearance of a product. 
GloI activity was determined by the rate of formation of the thiol ester S-D-
lactoylglutathione (from the methylglyoxal(MGO)-glutathione(GSH) hemithioacetal) at 240 
nm, the extinction coefficient ε being 3.37 mM-1 cm-1(Ridderström and Mannervik, 1996b). 
The GloI standard assay mixture was defined as follows: 100 mM potassium phosphate 
(with 100 mM KCl for cGloI), pH 7.0, 0.01-0.5 mM of the hemithioacetal (MGO-GSH) 
were incubated for 5 minutes and the reaction was started by adding GloI. The total assay 
volume was 1 ml. For a desired concentration of MGO-GSH, the required concentrations of 
MGO and glutathione (GSH) were calculated from the equations below. Excess free GSH in 
the assay was 0.1 mM and the dissociation coefficient for MGO-GSH was 3 mM. 
One unit of GloI catalyzes the formation of 1 µmol of S-D-lactoylglutathione per minute. 
Specific activity and kcat values were calculated according to the Michaelis-Menten equation 
and derived from Lineweaver-Burk plots, respectively. Kinetic measurements were carried 
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out at 30°C to compare values obtained with those previously reported for human GloI 
(Ridderström and Mannervik, 1996b).  
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For measuring GloII activity, the decrease in absorbance resulting from S-D-
lactoylglutathione  (ε 240 nm = 3.1 mM
-1cm-1) hydrolysis was measured at 25°C in 100 mM 
MOPS buffer, pH 7.2 in a total volume of 1 ml. S-D-lactoylglutathione concentrations 
varied from 0.05 mM to 0.5 mM; higher concentrations of S-D-lactoylglutathione were 
limited by its high absorbance at 240. The reaction was started by addition of GloII. One 
unit of GloII catalyses the hydrolysis of 1 µmol of S-D-lactoylglutathione per minute. Km 
and kcat values of human GloII for S-D-lactoylglutathione had previously been reported 
(Ridderström et al., 1996) using the GloII DTNB [5,5’-dithiobis(2-nitrobenzoate)] assay. 
The release of 5-thio-2-nitrobenzoate from the reduction of DTNB by GSH (product of the 
GloII reaction) is monitored spectrophotometrically at 412 nm (ε 412 nm = 13.6 mM
-1 cm-1). 
Both cGloII and human GloII were tested in the DTNB assay with S-D-lactoylglutathione 
concentrations ranging from 20 to 1800 µM at 37°C. 
TrxR was assayed in a total volume of 500 µl in 100 mM potassium phosphate, 2 mM 
EDTA, pH 7.4, with 100 µM NADPH and appr. 10 mU/ml TrxR. The reaction at 25 °C 
was monitored by the decrease in absorbance at 340 nm and was started without 
preincubation (< 30 sec.) with 20 µM PfTrx. 
The activity of LipDH was normally assayed in 47 mM potassium phosphate buffer, pH 
6.9 containing 200 mM KCl and 1 mM EDTA by monitoring at 340 nm the decrease in 
NADH concentration (ε being 6.22 mM-1 cm-1) upon transfer of reducing equivalents to 
lipoamide. However, due to the photoreactive effects of MB with EDTA, assays in which 
the stimulatory/inhibitory effects of MB on PfLipDH1 were tested, were carried out simply 
in 50 mM potassium phosphate buffer pH 7.4. All assays were carried out at 25°C in the 
presence of either 100 µM NADH (for normal assays) or 200 µM NADH (for MB-related 
assays) 
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Activity of all the enzymes was determined according to the following equation. 
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whereby ∆A/min = change in absorbance per minute, Vo = total volume of assay, ε = extinction coefficient 
and Vi = volume of enzyme solution in assay 
 
 
3.11   Inhibition studies 
The S-(N-hydroxy-N-arylcarbamoyl)glutathiones were tested as inhibitors of P. falciparum 
GloI and GloII. GloI inhibition was studied at 25°C in the assay system described above. 
GloII inhibition by S-(N-hydroxy-N-arylcarbamoyl)glutathiones was studied in the 
standard GloII assay. Three inhibitor derivatives were tested which differ in the nature of 
their aryl group, namely S-(N-hydroxy-N-phenylcarbamoyl)glutathione (HPC-GSH), S-(N-
hydroxy-N-chlorophenylcarbamoyl)glutathione (HCPC-GSH) and S-(N-hydroxy-N-
bromophenylcarbamoyl)glutathione (HBPC-GSH) (Figure 10; Murthy et al., 1994). P. 
falciparum Glos were directly compared with their human counterparts. S-p-
bromobenzylglutathione, a GloI inhibitor whose diethyl ester prodrug was previously 
reported to inhibit the growth of P. falciparum in culture with IC50 values approximating 5 
µM (Thornalley et al., 1994), was also tested as cGloI inhibitor. The DTNB assay 
described above was employed for testing weak glyoxalase II inhibitors (namely; S-(p-
azidophenacyl)glutathione, S-propylglutathione and S-hexylglutathione) which showed 
high absorbance at 240 nm. 
Eleven novel TrxR inhibitors were obtained from Professor Charles Williams (Ann Arbor, 
USA) within the frame of a scientific collaboration. All 11 inhibitors were initially 
assessed in direct comparison on P. falciparum and human TrxR by Christine Nickel and 
based on a selective inhibition of PfTrxR criteria – as determined by IC50-values under 
standardized conditions – three were chosen for further characterization of their mode of 
inhibition and influence on P. falciparum cultures. These three inhibitors were 4-nitro-
2,1,3-benzothiadiazole (compound 1), 6,7-nitroquinoxaline (compound 2) and bis-(2,4-
dinitrophenyl) sulfide (compound 3). For characterization of the inhibition type, varying 
amounts of inhibitor and substrates (PfTrx and NADPH) were employed. 
Methods 42
 
 
Figure 10:  Structure of the S-(N-hydroxy-N-arylcarbamoyl)glutathiones 
A). S-(N-hydroxy-N-phenylcarbamoyl)glutathione (HPC-GSH), B). S-(N-hydroxy-N-
chlorophenylcarbamoyl)glutathione (HCPC-GSH) and C). S-(N-hydroxy-N-bromophenyl 
carbamoyl)glutathione (HBPC-GSH) 
 
 
3.12   Glutathionylation assays 
In order to induce glutathionylation, fully reduced (to ensure availability of free cysteine-
SH groups) PfTrx was incubated at a concentration of 10 µM with 5 mM GSSG at room 
temperature for 2 hours or at 4°C for a couple of days. After the incubation period, control 
samples without GSSG as well as GSSG-treated samples were further treated with 2 mM 
iodoacetamide in order to block residual cysteine-SH groups. Identification of glutathione 
on PfTrx was carried out either by western-blotting using anti-glutathione antibodies or by 
matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF/MS) after tryptic digestion of the PfTrx samples by Sasa Koncarevic. 
 
3.13   Metal ion analysis 
Zinc, iron and nickel contents of all P. falciparum glyoxalases were determined by atom 
absorption spectroscopy (Dr. V. Muntean, Seelig Analytical Laboratories, Karlsruhe, 
Germany). The protein samples were exhaustively dialysed against a 4 mM potassium 
phosphate buffer, pH 7.0, which also served as a blank in these experiments. 
 
3.14   Structure prediction of glyoxalase enzymes 
Models of cGloI, tGloII, and cGloII are based on the crystal structures of homodimeric 
human glyoxalase I in complex with HIPC-GSH (Cameron et al., 1999a) and human 
glyoxalase II (Cameron et al., 1999b), respectively (Protein Data Bank accession numbers 
1qin and 1qh5, respectively). Alignments were optimized manually in the Swiss-PDB 
Viewer (spdbv). Computations of the models were carried out at the Swiss-Model server 
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(Guez and Peitsch, 1997; Schwede et al., 2003), and force field energies of the models 
were calculated with the GROMOS96 implementation of spdbv. 
 
3.15   Protein crystallization 
3.15.1 Crystallization screening 
The goal of the crystallization experiments was to produce crystals of the glyoxalase 
enzymes that are suitable for X-ray diffraction analysis. This diffraction pattern can then be 
analyzed to discern the protein’s three-dimensional structure. As such, highly concentrated 
protein samples (minimum of 8 mg/ml) with purity of at least 95% are required. Based on 
the yields obtained after protein purification, crystallization trials were carried out for 
cGloI, GILP and cGloII. tGloII was very unstable and only small amounts could be 
obtained after purification, so crystallization trials could not be carried out. PfLipDH1 and 
PfLipDH2 could likewise not be set for crystallization due to the  small quantities obtained 
in overexpressions. 
In trials to develop protein crystals of the glyoxalase enzymes, the hanging drop method 
was used. The hanging drop method relies on the vaporisation of water or a volatile agent 
between a micro-drop of mother liquor and much larger and highly-concentrated reservoir 
solution, thereby causing a slow precipitation of the protein within the drop. Ideally, 
individual protein molecules align themselves in a repeating series of "unit cells" by 
adopting a consistent orientation. In the hanging drop method, drops are prepared on 
siliconized microscope glass cover slips by mixing 2 µl of protein solution with the same 
volume of precipitant solution. The cover slip is placed over a small well containing 800 µl 
of the precipitating solution (Figure 11). By use of a crystallization kit (Crystal screen I 
and II, Hampton Research), up to 100 different solutions with variations in pH, ionic 
strength, metallic content, and buffer systems were tested initially on each of the 
glyoxalases. The proteins were previously dissolved in 50 mM sodium phosphate buffer 
pH 8.0, containing 300 mM NaCl. The proteins were kept under different temperatures 
(4°C, 15°C, 24°C or 30°C) after being set as shown below for at least one week to allow 
for the development of the crystals. 
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Figure 11:  Diagram of hanging drop method.  
Reservoir solution (blue) usually contains buffer and precipitant. Protein solution (red) 
contains the same compounds, but in lower concentrations. 
 
3.15.2 Crystallization optimization 
Optimal conditions for crystallization of a novel protein are difficult to predict. Every 
macromolecule is unique in its physical and chemical properties and its three-dimensional 
structure with distinctive surface characteristics. The variables influencing crystal growth 
are too many to allow an exhaustive search. 
Optimization for the development of crystals generally involved the addition of additives 
(e.g. β-octylgalactoside, maltoside) in the protein drop of the coverslide. In order to 
prevent the development of salt crystals, the glyoxalase proteins were dissolved in 50 mM 
sodium phosphate buffer containing 100 mM NaCl instead of 300 mM NaCl. By use of the 
buffer system and conditions (25-30% w/v PEG 2000 monomethyl ether in 50 mM MES 
pH 5.8 containing 100 mM NaCl; 15°C) under which crystals were obtained for the human 
GloI (Cameron et al., 1999a), cGloI and GILP were optimized for crystal development. 
Several variations of this buffer system included bidirectional changes in the pH, 
concentration of PEG 2000 monomethyl ether and MES, and temperature. 
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3.16   Cell culture experiments 
Intraerythrocytic stages of P. falciparum strains were cultured according to Trager and 
Jensen (1976) with slight modifications. Typically, parasites were propagated in leukocyte-
free erythrocytes (A+) at 3.3 % haematocrit at 37°C under reduced oxygen (typically 3% 
O2, 3% CO2, 95% N2) in tissue culture (RPMI 1640 – Gibco) medium containing 4% 
human serum (A+) and 0.2% Albumax (lipid-rich bovine serum albumin). Albumax 
appears to reduce both the rate at which erythrocytes deteriorate in vitro and pH drift when 
cultures are exposed to ambient air. The media were further supplemented with 9 mM 
(0.16%) glucose, 0.2 mM hypoxanthine, 2.1 mM L-glutamine, and 22 µg/ml gentamycin. 
CQ sensitive (3D7 and HB3) and resistant (K1 and Dd2) strains of P. falciparum (Su et al., 
1997) were grown in continuous culture according to the needs of each experiment. 
Characteristics of the P. falciparum strains employed in this study are shown in Table 5. 
Day to day monitoring of parasite growth was carried out by observation of parasitaemia 
on Giemsa-stained thin-blood films. Depending on the strain, parasites typically propagate 
3-8 fold every 48 hours, thus care was taken to avoid parasite cultures attaining too high 
parasitaemia for adequate growth (3-10%). Percentage parasitaemia used in experiments 
also varied according to the experiment.  
 
Table 5:  Characteristics of Plasmodium falciparum strains employed (Fidock et al., 
2004; Su et al., 1997; Akoachere et al., in press). 
 
Name Clone Drug 
resistance 
Multiplication 
rate 
Chloroquine 
IC50 value in 
nM 
3D7 Yes (from 
NF54) 
- 4-5 8.6 ± 0.4 
HB3 Yes 
 
PYR 6 16.8 ± 0.5 
Dd2 Yes (from 
WR’82) 
CQ, QN, PYR, 
SDX 
5-6 90.2 ± 10.6 
K1 No CQ, PYR 4-5 155 ± 11.4 
CQ, chloroquine; QN, quinine; PYR, pyrimethamine; SDX, sulfadoxine. 
 
3.16.1 Synchronization 
Synchronisation of parasites in culture to ring stages was carried out by treatment with 5% 
(w/v) sorbitol (Lambros and Vanderberg, 1979) which warrants a predominantly ring 
phase culture of about 10% parasitaemia. Five millilitres of 5% sterile sorbitol preheated to 
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37°C was added to 0.5 ml parasitized erythrocytic pellet from culture and left for 5 minutes 
at 37°C. The sorbitol mixture was then centrifuged at 1900 rpm for 3 minutes at room 
temperature to spin down the erythrocytes. The sorbitol was then off-aspirated and the 
pellet rapidly resuspended in complete medium for a quick wash after which the pellet was 
returned to culture. If the culture was not sufficiently synchronised, the procedure was 
repeated after 48 hours when the culture was in the ring form again. 
 
3.16.2 Studies on MB uptake 
Young P. falciparum trophozoites were incubated for 12 h with 13 nM, 26 nM, or 39 nM 
MB. Non-parasitized red blood cells (NPRBC) were treated identically. After 12 h, cell 
cultures were centrifuged at 750 × g for 3 minutes at 25°C. The supernatants representing 
the cell culture medium were immediately frozen. In parasitized red blood cells (PRBC), 
erythrocytic and parasitophorous vacuolar membranes were lysed by treatment with 0.02% 
w/v saponin for 10 minutes at 37°C. After another centrifugation step the supernatants 
were stored at -80°C. The parasites in the pellet were washed three times in saponin buffer 
and disrupted by three times freezing and thawing in liquid nitrogen followed by 
sonication on ice. After centrifugation (31000 × g, 30 min, 4°C) parasite lysate was 
obtained in the supernatant and parasite debris in the pellet. NPRBC were washed twice in 
phosphate buffered saline (PBS) before being disrupted by freezing and thawing. MB was 
determined in various compartments by high performance liquid chromatography coupled 
to tandem mass spectrometry (LC/MS/MS) (Rengelshausen et al., 2004). In brief, in vitro 
samples (up to 100 µl of incubation media, cell suspensions, or parasite lysates) were 
processed by adding 200 µl of precipitation reagent (acetonitrile), vortex-mixing for 15 s, 
and centrifugation for 10 min at 2500 × g. The clear supernatants were transferred into 
autosampler vials for LC/MS/MS analysis. 
 
3.16.3 Determination of enzymatic activity from parasitic extracts 
In order to test the effects of Glo inhibitors on Glo activity in the parasites, P. falciparum 
cultures with 15% parasitaemia and 3.3% haematocrit were treated for 8 hours with 10 µM 
(2 x IC50) S-p-bromobenzylglutathione cyclopentyldiester. Then the parasites were isolated 
by suspending the erythrocytes in a 20-fold volume of saponin buffer containing 7 mM 
K2HPO4, 1 mM NaH2PO4, 11 mM NaHCO3, 58 mM KCl, 56 mM NaCl, 1 mM MgCl2, 14 
mM glucose, and 0.02% saponin (pH 7.5 at 25°C) for 10 minutes at 37°C. Following 
centrifugation (2700 rpm, 3 min, 25°C) the pellets were washed three times at 25°C with a 
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20-fold volume of buffer. The parasites were disrupted by four times freezing in liquid 
nitrogen and thawing, followed by sonication for 2 x 10 seconds. After a cleaning spin 
(50000 rpm, 60 min, 4°C), protein content of the parasite extracts was determined using 
the BioRad (München, Germany) protein dye assay with bovine serum albumin serving as 
a standard (Bradford, 1976). GloI and GloII activities were determined in the same 
extracts. 
 
3.16.4 Drug susceptibility tests 
3.16.4.1 WHO microtest 
The microtest was developed by Rieckman et al. (1978) and adopted by WHO for 
epidemiologic monitoring of drug-resistant malaria, requires a parasite count under the 
microscope to measure the capacity of antimalarial drugs to inhibit parasite maturation to 
the schizont stage. The assay was modified such that the ability of the drug to inhibit 
growth of the parasites after a complete cycle of 48 hours (rings to rings) was measured. 
In a 24 well culture plate containing parasite culture at 1% parasitaemia and 3.3% 
haematocrit in each well, the drug of interest is applied in duplicates at various 
concentrations. Control wells with no drug or no drug plus necessary vehicule (DMSO or 
100% ethanol) are also reserved on the same culture plate. The parasites are exposed to the 
drug for a considerable amount of time depending on the experiment after which the 
medium is replaced with fresh medium and allowed to grow for another 24 hours to allow 
completion of a full erythrocytic cycle of the parasites. Thin-filmed smears on glass slides 
are then prepared from the culture material of each well. The smears are then methanol 
fixed and then stained in freshly prepared Giemsa solution. The respective percentage 
parasitaemia is counted under a light microscope and the difference in percentage 
parasitaemia as compared to that of untreated slides, is considered proportional to the 
effect of growth inhibition of the parasites by the drug. The counted parasitaemia is plotted 
against the corresponding drug concentration on a logarithmic dose response curve and the 
IC50 value (drug concentration that inhibits 50% of the parasite growth in comparison with 
drug-free controls) of the drug is extrapolated from the curve. 
 
3.16.4.1.1  Effects of the S-(N-hydroxy-N-arylcarbamoyl)glutathiones – Glo      
                         inhibitors - in P. falciparum cultures 
Intraerythrocytic stages of the chloroquine resistant P. falciparum strains K1 and Dd2 were 
applied in the above described WHO microtest as follows. Sorbitol-synchronised parasites 
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in the ring stage were used for testing the effects of two different pro-drug forms of HCPC-
GSH, namely the HCPC-GSH diethylester and the S-(N-hydroxy-N-chlorophenyl 
carbamoyl)sulfoxide on P. falciparum in culture. It is worth noting that potent inhibitors of 
glyoxalases are usually GSH derivatives which as a result of the diacid nature of GSH are 
not membrane-permeable; therefore pro-drug derivatives are being used. The dialkylester 
pro-drug of the inhibitor depends on the presence of unspecific intracellular esterases to 
generate the active drugs within the cell (Lo and Thornalley, 1992; Kavarana et al., 1999) 
as indicated below. 
 
 
The alkylsulfoxide depends on an acyl interchange with GSH within the cell (Hamilton et 
al., 1999).  
 
 
Synchronised parasites (1.5% parasitaemia, 3.3% haematocrit, 500 µl total volume) were 
exposed for 24 hours to 0.1 µM -100 µM prodrug. The parasites were then incubated in 
inhibitor-free medium for another 24 hours to complete the P. falciparum life cycle of 48 
hours. Growth inhibition was quantified by counting parasitized red blood cells using 
Giemsa-stained slides of thin blood smears. 
 
3.16.4.1.2   Testing of PfTrxR inhibitors compounds 1, 2 and 3, in cultures 
 
The strain used was the chloroquine-resistant strain K1, which was synchronized at the 
ring stage. Parasitemia was adjusted to 1-1.5 % and hematocrit to 3.3 %. For each 
inhibitor, 12 wells with 495 µl and 2 with 500 µl of this culture were prepared. The 
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inhibitors were dissolved in DMSO ad 10 mM. This stock was stepwise diluted ad 10 µM, 
1µM, 0.1 µM and 0.01 µM with DMSO. All inhibitor solutions were sterile filtered. 
Of each solution 5 µl was added to an incubation well reaching 500 µl end volume, 1% 
DMSO and final inhibitor concentrations of 100, 10, 1, 0.1 and 0.01 µM, respectively. 
Every approach was prepared twice for each inhibitor. Also carried out twice were controls 
without any addition and with 1% DMSO, respectively. 
Cultures were monitored after 24 and 48 h. Parasitemia was determined by counting 
Giemsa-stained parasites under the microscope. 
 
3.16.4.1.3   Stage specificity of MB action 
IC50 values for MB were determined on different synchronized blood stage forms (rings, 
trophozoites, and schizonts) of the P. falciparum strain K1. For this purpose, aliquots of a 
parasite culture synchronized to the ring stage (t = 0) were drawn every 3 to 6 h throughout 
the 48 h cycle and exposed to various MB concentrations. Considering the multiplication 
of the parasites towards the end of the cycle, the parasites to be treated at 39, 42, and 48 h, 
were diluted with A+ erythrocytes by factors of 1:2, 1:4 and 1:7, respectively. Parasites 
were exposed to the drug for 6 h followed by a change of the medium and undisturbed 
growth for 42 h to complete a full cycle. Parasite growth and parasitaemia were monitored 
by assessing Giemsa-stained blood smears under the microscope. 
 
3.16.4.2 Semi-automated microdilution method 
Isotopic drug sensitivity assays by means of the semi-automated microdilution technique 
(Desjardins et al., 1979) were employed to investigate the susceptibility of the malaria 
parasites to clinically-used antimalarials as well as TrxR and Glo inhibitors of particular 
interest to us which had shown anti-enzymatic effects in the nanomolar range. The method 
depends on the incorporation of radioactive 3H-hypoxanthine – which is taken up by the 
parasite as a precursor of purine deoxynucleotides for DNA synthesis – and was performed 
according to the modifications of Fivelman et al. (2004).  
In 96 well microtitre plates (NuncR), a two-fold serial dilution of the starting concentration 
of each drug to be tested (B1-B12) was carried out so that each well contained 100 µl of 
half the drug concentration of the above-preceding well (Figure 12). 100 µl of a 2 times 
stock of previously diluted parasites at a parasitaemia of 0.5% and a haematocrit 2.5% 
were added onto each well so that the parasites were finally at a parasitaemia of 0.5% (> 
70% rings) and 1.25% haematocrit. These dilutions were carried out in hypoxanthine-free 
medium. Positive control wells contained parasitized red blood cells (PRBC) while the 
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negative control wells contained non-parasitized red blood cells (NPRBC). The starting 
concentration of each drug was chosen such that the IC50 value (drug concentration that 
produces 50% reduction in the uptake of 3H-hypoxanthine) falls within the middle of the 
plate. The plate was then incubated as normal culture and after 48 hours, 50 µl (final 
concentration of 0.5 µCi/well) of [3H]-hypoxanthine was added per well and the plate was 
further incubated. After a further 24 hours, the plates were placed at -80°C for at least 1 
hour to freeze the cells. Plates were then thawed, each well was harvested on a glass fibre 
filter (Perkin-Elmer, Rodgau-Jügesheim, Germany), dried, and radioactivity in counts per 
minute (cpm) from each well measured in a β-counter was considered to be proportional to 
the respective growth of P. falciparum in the well. For the experiments, P. falciparum 
strains with different CQ sensitivity (3D7, HB3, Dd2, and K1) were employed (Su et al., 
1997). Percentage reductions were used to plot percentage inhibition of growth as a 
function of drug concentrations. IC50 values were determined by linear regression analyses 
on the linear segments of the curves (IC90 values could also be determined by curve-fitting 
and could provide a useful measure of variation between experiments).  
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Positive control Negative control 
B 
C 
D 
E 
F 
G 
H 
Drug 1 
 
Drug 2 
 
Drug 3 
 
Drug 4 
 
Drug 5 
 
Drug 6 
 
 
Figure 12:  Semi-automated microdilution method: Arrangement of drugs on a 96 well plate. 
A1-A8: positive control, red cells and parasites 
A9-A12: negative control, red cells only (no parasites) 
B1-H12: Serial drug dilutions for 6 compounds in duplicate. Arrow indicates direction of 
decreasing drug concentration 
 
Drugs that were tested for parasitic susceptibility by this method included CQ, MB, 
artemisinin, artesunate, artemether, piperaquine, amodiaquine, quinine, mefloquine, 
primaquine, pyrimethamine, and the PfTrxR inhibitor, compound 1. Assays were typically 
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repeated on two or three separate occasions. Within each experiment standard deviations 
were typically less than 10% of the mean. Differences in parasite stages could lead to up to 
two-fold shifts in the IC50 values between experiments; however, these differences rarely 
affected the overall relationships between the parasite strains with respect to their 
differences in drug response. 
 
3.16.4.3 Drug combination assays 
In order to assess the effects of combined drugs, isobologram analysis was performed to 
assess whether two drugs were additive, synergistic or antagonistic. This was mostly 
applied to test the effects of MB in combination with other clinically used antimalarials. 
The two drugs to be tested in combination were applied alone and in fixed concentration 
ratios of 1:1, 1:3, and 3:1 as described by Fivelman et al. (2004). A CQ control is applied 
in the position of the sixth drug as the IC50 values of CQ had already been standardized in 
the laboratory for all the strains of P. falciparum. This had the advantage that day to day 
variations in the IC values could be easily monitored. IC50 and IC90 values were calculated; 
the fractional inhibitory concentrations (FIC) of the respective drugs were determined 
(Fivelman et al., 2004) based on the following definitions below (Ohrt et al., 2002). 
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For these studies P. falciparum strains with different CQ sensitivity (3D7, HB3, Dd2, and 
K1) were employed (Su et al., 1997). 
Drug combination effects of the PfTrxR inhibitor compound 1 with CQ, MB and 
artemisinin were assessed using this method. Most importantly were the combinations 
involving MB and some clinically used antimalarials like CQ, artemisinin, artesunate, 
artemether, piperaquine, amodiaquine, quinine, mefloquine, primaquine and 
pyrimethamine. The above combinations were carried out on the CQ-resistant P. 
falciparum strain K1 in order to determine which drug combinations could be clinically 
useful in the treatment of resistant falciparum malaria. Drug combination assays of MB 
with the artemisinins were extended to other strains of P. falciparum with varying CQ 
sensitivies (Dd2, HB3 and 3D7). 
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3.16.5 Statistics 
IC50 values were determined for each drug alone and for drugs in fixed concentration ratios 
by fitting a logistic dose-response equation to the concentration-response curves. IC50 and 
IC90 values were used to calculate 50% and 90% fractional inhibitory concentrations, 
respectively (FIC50 and FIC90). Mean IC and FIC values obtained for the various drugs and 
corresponding parasite strains were used for statistical analyses (Ohrt et al., 2002; 
Fivelman et al., 2004). The unpaired Student’s t-test was used to compare differences 
between IC50 values of MB obtained for CQ-sensitive and CQ-resistant strains. Pearson 
correlation was used to assess the correlation between IC values of MB and CQ as well as 
between MB and the artemisinins. Least square means (LSMeans) was used to compare 
differences in FICs obtained in the combination of MB with the artemisinins with respect 
to the three different artemisinins and the different combination ratios. Statistical Analysis 
Software (SAS) was used for statistical computations. For all statistical tests, the 
significance level (P) was set at 0.05. 
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4 Results 
4.1 The glyoxalase system 
4.1.1 Recombinant production of P. falciparum glyoxalases 
Screening the Plasmodium falciparum genome sequencing database with different known 
GloI and GloII genes resulted in the identification of a second putative GloI gene from 
chromosome 6 and two putative GloII genes from chromosome 4 and chromosome 12, 
respectively. Designed perfect match primers were employed in PCR reactions (Table 2) 
using P. falciparum cDNA as template and the resulting products of expected size were 
cloned into the expression vector pQE30 and sequenced. The sequences were in full 
agreement with the respective sequences found in the genomic database.  
The basic characterization of the cGloI gene product (see Figure 13 for sequence 
information referring to the 3-D model) had been reported previously (Iozef et al., 2003). 
The GILP gene from chromosome 6 consists of 924 bp and its gene product of 307 amino 
acids contains an N-terminal apicoplast targeting sequence with high probability (>98%, 
PATS 1.2.1N, Zuegge et al., 2001). High sequence identities were obtained with the 
respective proteins from other Plasmodium species (e.g. 67% identity with P. yoelii) but 
only low identities were found with proteins from other species, the highest value being 
25% identity with Arabidopsis thaliana. The gene product (without His-tag, with targeting 
sequence) had a calculated molecular mass of 35.8 kDa, an isoelectric point of pH 8.59 and 
an ε280 nm of 33.6 mM
-1cm-1.  
The tGloII and cGloII genes from chromosome 12 and 4 consist of 840 bp and 792 bp, 
respectively. Alignments of the amino acid sequences of P. falciparum glyoxalases II with 
those from other species showed identities of up to 32% (tGloII with Gallus gallus and 
Cicer arietinum) and 43% (cGloII with man and Danio rerio) (Figure 14). tGloII contains 
an N-terminal putative targeting sequence which was deleted in the cloning process to 
improve solubility and stability of the protein. As deduced from its DNA sequence, tGloII 
is composed of 322 amino acids; the N-terminally truncated active form of the protein has 
267 amino acids with a molecular mass of 31.8 kDa and an isoelectric point of pH 7.25. 
cGloII is composed of 263 amino acids with a molecular weight of 30.5 kDa and an 
isoelectric point of pH 7.64. Extinction coefficients ε at 280 nM were 27.12 mM-1cm-1 and 
17 mM-1cm-1 for tGloII and cGloII, respectively. 
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PfGloIC        -----------------NYKNITN-------FSQTMIRVKNPEKSLYFYIHILGMKLIHV  208 
HsGloI         MAEPQPPSGGLTDEAALSYCSDADPSTKDFLLQQTMLRVKDPKKSLDFYTRVLGMTLIQK   60 
PfGloIN        -----------MAQEISNLVKKYNVT-----WQQTMLRIYDPKETVEFYEKNFGMINIHT   44 
                                .  .  :        .***:*: :*:::: ** : :**  *:  
 
PfGloIC        KHCSD--FSLYFLKSNYACAENNKEMIEDQSNKNTNEIYDFNSLKNSYQTDEDYENFKQS  266 
HsGloI         CDFPIMKFSLYFLAY-----EDKNDIPK---EKDEKIAWALSRK----------------   96 
PfGloIN        YHFNEYNFSLYFLITPPYDEEERKKLPEPNTKESEKYLWNLNTV----------------   88 
                      ****** .     *:.... .  . .    .: :.                            
 
PfGloIC        WEPVLELTHNHGTEDDDNFSYHNGNTE-PRGFGHIGFLVNDLENYCKELETLNVTFKKKVT 326 
HsGloI         --ATLELTHNWGTEDDETQSYHNGNSD-PRGFGHIGIAVPDVYSACKRFEELGVKFVKKPD 154 
PfGloIN        ---CLELTYNHNSQEK----LSNGNNENDRGFGHIAFNCNDVIEQCDNLFKKNVKFHKLPH 142 
                   ****:*. :::..  . :***.:  ******::   *: . *..:   .*.* *    
 
PfGloIC        EGLMKNIAFIYDPDNYVIELIQRDTSFIAK 356 
HsGloI         DGKMKGLAFIQDPDGYWIEILNPNKMATLM 184 
PfGloIN        ETKMKTIGFALDPNNYWIEIVKRSNQVKWK 172 
 
 
Figure 13:  Alignment of N- and C-terminal halves of P. falciparum glyoxalase I with human 
glyoxalase I.  
Residues involved in the formation of the active Zn2+ coordination site are indicated by 
red letters, while those involved in the formation of the hydrophobic binding pocket are 
shown in blue. Putative metal-defining inserts (Sukdeo et al., 2004) are underlined.  
 
 
 
Freshly transformed E. coli cells were employed for overexpression of the P. falciparum 
Glo genes (Table 2) and, as shown in Table 3, the hexahistidyl-tagged recombinant 
proteins were purified over Ni-NTA columns. cGloI and tGloII were pre-purified on an S-
hexylglutathione agarose column. Yields and experimental details are shown in Table 3. 
After overexpression in E. coli M15 cells, the gene product of GILP was insoluble. Three 
shorter variants of the GILP gene were then cloned and overexpressed in E. coli BL21 cells 
in order to remove the N-terminal apicoplast signal sequence from the gene products. Gene 
products of these shorter variants designated ∆20GILP, ∆23GILP and ∆43GILP lacked the 
first 20, 23 and 43 amino acids of the complete GILP sequence, respectively. These 
variants were soluble and could be purified to homogeneity on Ni-NTA columns with 
yields of about 5 mg per litre cell culture. 
The theoretical molecular weights of the glyoxalase enzymes corresponded to those seen in 
SDS-PAGE (Figure 15). 
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HsGloII         ------------------------------------------------------------ 
AtcGloII        ------------------------------------------------------------ 
PfcGloII        ------------------------------------------------------------ 
ScGloII         ------------------------------------------------------------ 
AtmGloII        MPVISKASSTTTNSSIPSCSRIGGQLCVWPGLRQLCLRKSLLYGVMWLLSMPLKTLRGAR  60 
PftGloII        ------------------------------------------------------------ 
                                                                             
 
HsGloII         -----------------MKVEVLPALTDNYMYLVIDDETKEAAIVDPVQPQKVVDAARKH  43 
AtcGloII        -----------------MKIFHVPCLQDNYSYLIIDESTGDAAVVDPVDPEKVIASAEKH  43 
PfcGloII        -------------MKPCAQVLVVPVLNDNFSYVIIDEKTKKAASIDPVEPDKVLKRIETA  47 
ScGloII         -------------MQVKSIKMRWESGGVNYCYLLSDSKNKKSWLIDPAEPPEVLPELTED  47 
AtmGloII        KTLKITHFCSISNMPSSLKIELVPCSKDNYAYLLHDEDTGTVGVVDPSEAAPVIEALSRK 120 
PftGloII        ---------------MCTNTIIIPFYKDNYSYIFYDDK-EEGIVVDPADYN-IINDISKK  43 
                                            *: *:. *...     :** :   ::       
 
HsGloII         G-VKLTTVLTTHHHWDHAGGNE------KLVKLESGLKVYGGD---DRIGALTHKITHLS  93 
AtcGloII        Q-AKIKFVLTTHHHWDHAGGNE------KIKQLVPDIKVYGGSL--DKVKGCTDAVDNGD  94 
PfcGloII        N-VELEYVLCTHHHYDHSGGN------IRMRELKQNIKVVGSAY--EPTPGVNEKVYDGQ  98 
ScGloII         EKISVEAIVNTHHHYDHADGNADILKYLKEKNPTSKVEVIGGSK--D-CPKVTIIPENLK 104 
AtmGloII        N-WNLTYILNTHHHDDHIGGN-------AELKERYGAKVIGSAVDKDRIPGIDILLKDSD 172 
PftGloII        ENIKIKHVLCTHKHSDHNNGNQ--------YYYEKNINVYGIKEY--DNKYINQDISNLT  93 
                   .:  :: **:* ** .**                :* *     .          .   
 
HsGloII         TLQVG-SLNVKCLATPCHTSGHICYFVSKPGGSEP------PAVFTGDTLFVAGCGKFYE 146 
AtcGloII        KLTLGQDINILALHTPCHTKGHISYYVNGKEG-EN------PAVFTGDTLFVAGCGKFFE 147 
PfcGloII        IIRLG-ELNIKAIHAPCHTKGHILYYVYKTDEAKQEDHKYKPILFTGDTLFIAGCGRFFE 157 
ScGloII         KLHLG-DLEITCIRTPCHTRDSICYYVKDPTTDER-------CIFTGDTLFTAGCGRFFE 156 
AtmGloII        KWMFA-GHEVRILDTPGHTQGHISFYFPGSAT-----------IFTGDLIYSLSCGTLSE 220 
PftGloII        HFQIN-NFKINIFLSNFHSKNQVSYLIENDNNKSK-----KNIFFTGDFLFISGIGKNFE 147 
                   .    ::  : :  *: . : : .      .         .**** ::  . *   * 
 
HsGloII         GTADEMCKALLEV-----LGRLPPDTRVYCGHEYTINNLKFARHVEPGNAAIREKLAWAK 201 
AtcGloII        GTAEQMYQSLCVT-----LAALPKPTQVYCGHEYTVKNLEFALTVEPNNGKIQQKLAWAR 202 
PfcGloII        GSAKDMFKNIEK------VKNMRKETLIYCGHEYTLNNLRFALSIENDNEYMKNKLNEVT 211 
ScGloII         GTGEEMDIALNNSILETVGRQNWSKTRVYPGHEYTSDNVKFVRKIYP--QVGENKALDEL 214 
AtmGloII        GTPEQMLSSLQK------IVSLPDDTNIYCGRENTAGNLKFALSVEPKNETLQSYATRVA 274 
PftGloII        QDNEDLYNSINKL-----KLLDKQNIYIFCGHEYTLDNLKFALTVDSTNKNLLSFYDHVV 202 
                   .::   :                 :: *:* *  *:.*.  :   .    .       
 
HsGloII         EKYSIGEPTVPS--TLAEEFTYNPFMRVREKTVQQHAGETDPVTTMRAVRRE-----KDQ 254 
AtcGloII        QQRQADLPTIPS--TLEEELETNPFMRVDKPEIQEKLGCKSPIDTMREVRNK-----KDQ 255 
PfcGloII        EKLKNKEHSVPS--TIEEENLINPFFRT--HCYVNKFNMNDEIKILDKLRQ--------- 258 
ScGloII         EQFCSKHEVTAGRFTLKDEVEFNPFMRLEDPKVQKAAGDTNNSWDRAQIMDK-----LRA 269 
AtmGloII        HLRSQGLPSIPT--TVKVEKACNPFLRISSKDIRKSLSIPDSATEAEALRRI-----QRA 327 
PftGloII        NS-NKNYPTVPT--LLEHEYLYNPFLRCDQNDVRKSIDLYAKKKNIKIQQESDYIVILRL 259 
                .         .    :  *   ***:*  .    .                          
 
HsGloII         FKMPRD-- 260 
AtcGloII        WRG----- 258 
PfcGloII        LKNNF--- 263 
ScGloII         MKNRM--- 274 
AtmGloII        RDRF---- 331 
PftGloII        MKDNFKAS 267 
 
 
Figure 14:  Alignment of glyoxalases II.  
Residues involved in binding of the substrate S-lactoyl-glutathione as shown for the 
human enzyme (Cameron et al., 1999b; Ridderström et al., 2000) are shadowed; the 
active site motif THxHxDH is boxed; two other conserved histidines required for zinc 
binding at the active site are indicated by red letters. GenBank accession numbers are 
given in parentheses: HsGloII, human glyoxalase II (CAA62483); AtcGloII, cytoplasmic 
Arabidopsis thaliana glyoxalase II (NM_111922); PfcGloII, Plasmodium falciparum 
cytoplasmic glyoxalase II (AY494055, Akoachere et al., 2005); ScGloII, Saccharomyces 
cerevisiae (CAA71335); AtmGloII, mitochondrial Arabidopsis thaliana (NP_565999); 
PftGloII, Plasmodium falciparum targeted glyoxalase II (AF486285, Akoachere et al., 
2005); the sequence of an N-terminally truncated form (55 aa) is given in this alignment. 
This short form of the protein was approximately 3.5-fold more active than the full-length 
protein. 
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Figure 15: SDS-PAGE of active recombinantly produced P. falciparum glyoxalases.  
Lane 1 – molecular weight markers, lane 2 – cGloI, lane 3 – tGloII and lane 4 – cGloII. 
 
 
4.1.2 Kinetic characterization 
The kinetic characterization of cGloI has previously been reported by Iozef et al., 2003. As 
shown in the present study, addition of ZnSO4 during the overexpression of cGloI resulted 
in increased catalytic activity and a decreased Km value. In addition, the former 
measurements were carried out under conditions of excess MGO and the assumption that 
GSH would be readily converted to the MGO-GSH hemithioacetal (Vander Jagt et al., 
1972; Iozef et al., 2003). In the present study, the substrate concentrations in each assay 
were calculated on the basis of the dissociation constant of the MGO-GSH adducts 
(Ridderström and Mannervik, 1996b). Differences in protein quality and the assay system 
chosen thus explain the kinetic values obtained here. In direct comparison with human 
GloI, cGloI showed higher kcat and lower Km values (Table 6).  
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Table 6:  Kinetic properties of P. falciparum and human glyoxalases I 
 
Glyoxalase I Km kcat Specific activity kcat/Km 
cGloI 28 ± 3 µM 6637 min
-1 150 U/mg 4.0 x 106 M-1s-1 
human GloI 90 ± 10 µM 2375 min
-1 110 U/mg 0.44 x 106 M-1s-1 
All values were obtained at 30°C. The P. falciparum glyoxalase I-like protein (GILP) was not 
active under the conditions tested (see Results). 
 
Different N-terminally truncated variants of GILP were successfully overexpressed in E. 
coli and purified. However, none of these variants showed GloI activity under the various 
conditions tested. Buffers tested were: i) 100 mM potassium phosphate, 0-300 mM KCl, 
pH 7.0, 6.6 or 6.0. ii) 100 mM Hepes, 1 mM EDTA, pH 7.4. iii)  50 mM Tris, pH 7.4. iv) 
100 mM MOPS, 1 mM EDTA, pH 6.0 or 6.7. Addition of several metals (ZnCl2, NiCl2, 
MnCl2, CoCl2, FeCl2, FeCl3) in concentrations up to 100 µM or addition of 0.5 mg/ml BSA  
to stabilize GILP did not lead to detectable activity, either. The tested GloI substrates were 
the methylglyoxal-GSH and glyoxal-GSH hemithioacetal adducts from methylglyoxal and 
glyoxal, respectively. 
Both P. falciparum glyoxalases II were capable of hydrolysing S-D-lactoylglutathione into 
D-lactate and GSH with a pH optimum of pH 7.6-7.8 for tGloII and 7.2-7.8 for cGloII. 
Their kinetic properties along with those of human GloII obtained in our laboratory are 
shown in Table 7. 
 
Table 7:  Kinetic properties of P. falciparum and human glyoxalases II 
 
Glyoxalase II Km kcat Specific activity kcat/Km 
tGloII 225 ± 25 µM 3860 min
-1 117 U/mg 0.29 x 106 M-1s-1 
cGloII 100 ± 10 µM 7175 min
-1 226 U/mg 1.19 x 106 M-1s-1 
human GloII 248 ± 25 µM 2782 min
-1 96 U/mg 0.19 x 106 M-1s-1 
All values were obtained at 25°C. Km values obtained at 37°C were 190 µM for cGloII, 208 µM for 
human GloII and 463 µM for the cGloIITyr185Phe mutant. 
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4.1.3 Inhibition studies 
The inhibitory effects of S-(N-hydroxy-N-arylcarbamoyl)glutathione derivatives on both P. 
falciparum and human glyoxalases are shown in Table 8. These derivatives, being 
hydrophobic transition state analogs of S-D-lactoylglutathione, showed Ki values on cGloI 
in the nanomolar range (see Figure 16A for HBPC-GSH) and on tGloII and cGloII in the 
micromolar range. When performing assays with these compounds as substrates in the 
absence of S-D-lactoylglutathione, no activity of cGloII could be observed at 
concentrations of up to 1 mM. 
 
Table 8:  IC50 and Ki values of S-(N-aryl-N-hydroxycarbamoyl)glutathiones on human 
and P. falciparum glyoxalases. 
 
IC50 / Ki in µM S-(N-hydroxy-N-
arylcarbamoyl) 
glutathione 
derivative cGloI 
human 
GloI 
tGloII cGloII 
human 
GloII 
HPC-GSH 10 / ND 2.5 / ND 185 / ND 6 / 6 10 / 8 
HCPC-GSH 0.11 / 0.08 0.09 / 0.05 30 / 50 2 / 0.7 1 / 0.7 
HBPC-GSH 0.06 / 0.06 0.06 / 0.03 20 / 30 1.6 / 0.5 0.85 / 0.7-1 
ND – Not determined; Values represent means of three independent determinations. 
 
S-p-bromobenzylglutathione competitively inhibited cGloI with a Ki value of 20 µM 
(Figure 16B). Human GloI was inhibited much stronger, the Ki being 0.17 µM.  
When tGloII was tested in inhibition assays with S-propylglutathione, S-hexylglutathione 
and S-(p-azidophenacyl)-glutathione, Ki values of 1.9 mM, 1.5 mM and 1.3 mM, 
respectively, were obtained. cGloII was even less sensitive to the compounds (data not 
shown). S-(p-azidophenacyl)-glutathione slightly activated the enzyme at concentrations of 
0.2 mM to 1 mM.  
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Figure 16:  Dixon plots comparing competitive inhibition of (A) HBPC-GSH and (B) S-p-
bromobenzylglutathione on P. falciparum glyoxalase I using the methylglyoxal-GSH 
adduct as substrate. 
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4.1.4 Metal ion analysis 
The catalytic mechanism of the GloI enzymes requires an octahedrally-coordinated 
divalent metal ion which coordinates the two oxygen atoms of the glyoxal moiety of the 
substrate, polarising them and facilitating the rearrangement, via an enediolate 
intermediate, to D-lactate (Himo and Siegbahn, 2001). GloII enzymes like other members 
of the metallo-beta-lactamase superfamily of proteins possess a characteristic dinuclear 
active site (Wenzel et al., 2004).  
A metal content of up to 1.2 zinc and 0.1 nickel ions was obtained for cGloI (Iozef et al., 
2003). According to sequence alignments, particular putative inserts responsible for 
defining GloI metal specificity to Zn2+ were found to be present in cGloI (Figure 13; 
Sukdeo et al., 2004). However, metal coordinating residues were not entirely conserved in 
GILP and accordingly the metal content measured was negligible. Furthermore, the gene 
fusion demonstrated for cGloI (Iozef et al., 2003) does not apply for GILP.  
tGloII showed a Zn2+ ion content of 1.7 ± 0.3 with insignificant amounts of other metals 
tested. cGloII had a rather low metal content of 0.05 and 0.26 for Zn2+ and Fe2+, 
respectively. This indicated that the enzyme was not completely saturated with metals at its 
active site. GloII activity was therefore tested in buffers enriched with Zn2+, Fe2+, Fe3+, 
Ni2+, Ca2+ and Cu2+ ions, respectively. Only Zn2+ activated the enzyme by a factor of ~ 2. 
As previously shown, cGloI is a zinc dependent enzyme (Iozef et al., 2003) which was 
further supported by the fact that overexpression in the presence of Zn2+ enhanced catalytic 
activity. GILP, however, did not bind significant amounts of metal ions and has no known 
central metal coordinating motifs, either. tGloII was shown to be clearly Zn2+ dependent 
whereas cGloII had a rather low metal content of 0.05 and 0.26 for Zn2+ and Fe2+, 
respectively, and could be slightly activated by zinc. A zinc dependency has been reported 
for other GloII, e.g. for GloII from Arabidopsis thaliana by Crowder et al. (1997). Also 
other metals were shown to bind to GloII, namely iron and manganese, especially if the 
enzymes were produced in media enriched with these metals (Wenzel et al., 2004). The 
Zn/metal binding motif T-H-X-H-X-D-H as well as the two other histidines required for 
zinc-binding are conserved in both P. falciparum GloIIs (Figures 14 and 19). 
 
4.1.5 Cell culture experiments 
IC50 values of 30 µM and 10 µM were obtained for HCPC-GSH diethyl ester and HCPC-
sulfoxide, respectively. Haemolysis could be observed when higher concentrations of both 
pro-drugs were employed. 
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In extracts from isolated trophozoites of the P. falciparum strain Dd2 the specific activities 
of glyoxalase I and glyoxalase II were 0.2 U/mg and 1.0 U/mg, respectively. Treatment 
with 10 µM S-p-bromobenzylglutathione cyclopentyl diester, a potent GloI inhibitor, in a 
parallel culture (see methods) led to 0.2 U/mg GloI and 0.7 U/mg GloII, respectively. The 
lack of induction of the glyoxalase system by the S-p-bromobenzylglutathione cyclopentyl 
diester might be explained by the fact that the P. falciparum enzymes, in contrast to human 
GloI, are not significantly affected by the inhibitor. 
 
4.1.6 Crystallization experiments 
Several attempts to develop glyoxalase crystals did not yield any real protein crystal from 
the three glyoxalase (cGloI, GILP and cGloII) enzymes that were used. On exploitation of 
the conditions that were used to obtain the human GloI crystals (PEG 2000 monomethyl 
ether as precipitant – Cameron et al., 1999a), microcrystals were received for cGloI. 
Further optimization did not lead to any improvement of the quality of the microcrystals. 
Crystallographic studies of the recombinant glyoxalase enzymes should have helped in the 
design and development of glyoxalase inhibitors that could have applications as anti-
malarial drugs. This is because the X-ray structure that would have resulted from the 
crystals could have served in facilitating the design of specific P. falciparum glyoxalase 
inhibitors. The fact that the X-ray structures of both human GloI and GloII have been 
completely solved and published (Cameron et al., 1997; 1999a and 1999b) supports the 
development of more specific and highly selective inhibitors of P. falciparum glyoxalases 
as the inhibitors would have been designed after a close structural comparison of human 
and P. falciparum target sites of the inhibitors. 
However, optimization of the crystallization screens of the glyoxalases continued with 
further crystallization trials of cGloI and GILP at the High Throughput Screening 
Laboratory of the Hauptmann Woodward Medical Research Institute (USA). With the help 
of crystallization robotics at this institute, about 1400 crystallization settings with varying 
precipitants, pH, buffer systems, and ionic strength, were simultaneously tested for the 
development of crystals. The results of these experiments indicated several promising 
conditions under which small-sized crystals (see examples in Figure 17) of cGloI 
developed. These conditions can now be tested further for the development of X-ray 
diffractable crystal sizes. 
Moreover, on the basis of the structure of GILP, it would be possible to decipher if the 
enzyme is actually a glyoxalase and also by exploiting its plasmodial specificity to validate 
it as a target for rational drug design against P. falciparum. 
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 Figure 17:  Crystals of cGloI 
Crystals were developed in the following precipitating solutions. A. 0.09 M 
HEPES-Na, pH 7.5 containing 0.18 M manganese chloride, 27% isopropanol and 
10% anhydrous glycerol. B. 0.1 M Hepes, pH 7.0 containing 2.48 M magnesium 
chloride. 
 
 
4.1.7 Plasmodium falciparum glyoxalase structure predictions 
Models of cGloI, tGloII and cGloII were generated based on the crystal structures of the 
human glyoxalases I and II, respectively. Monomeric cGloI comprises two potential active 
sites which are presumably very similar to the active sites of the human homodimer 
(Figures 13 and 18A). Gln18, Glu91, His299, and Glu345 coordinate the first zinc ion, and 
His115, Glu161, Gln182, and Glu272 bind a zinc ion at the second active site. Like in 
yeast GloI both active sites presumably act independently of each other (Frickel et al., 
2001). Most of the residues involved in the formation of a hydrophobic binding pocket at 
the active site of human GloI (Kalsi et al., 2000) are also conserved in cGloI (Figures 13 
and 18B). Conserved residues of the hydrophobic binding pocket in cGloI are Phe47, 
Phe52, Leu54, Phe56, Leu85, Phe335 and Met330. Cys60, Ile88 and Leu160' (of the other 
subunit) in human GloI are replaced by Tyr45, Tyr81 and Ile333 in cGloI, respectively. 
Moreover, greater binding affinity (reflected by lower Ki) to cGloI with increase in 
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hydrophobicity of the S-(N-hydroxy-N-arylcarbamoyl)glutathiones was observed. This is 
in support of the postulated hypothesis of Kalsi et al. (2000) that occupancy of this pocket 
maximizes polar interactions between the enzyme and the bound enediol analogues. 
Despite the sequence similarities, a complete model of cGloI could not be generated due to 
a distance of 2.5 nm between Met138 and Ser25' of human GloI which are aligned to 
Lys172 and Tyr174 of cGloI. In addition, the residues corresponding to Met1-Pro24 of 
human GloI are missing in cGloI. Thus, the real structure of monomeric cGloI is likely to 
differ significantly from the human dimeric enzyme. Such significant differences could be 
exploited in the synthesis of specific inhibitors of cGloI. It was not possible to generate a 
model of GILP based on human GloI due to limited sequence similarity. 
 
Structures and calculated force field energies (-8.8 MJ/mol) of tGloII and cGloII are very 
similar to the used template (Figure 19). The residues coordinating two zinc ions at the 
active site are conserved and the resulting metal binding site is also very similar for the 
three glyoxalases II (Figures 14 and 20). However, several residues contributing to the 
glutathione-binding site differ between tGloII, cGloII and human GloII (Figures 14 and 
21). Arg249, Lys143 and Lys252 are thought to interact with the carboxylate group of the 
glycine of glutathione. In tGloII, two of these basic residues are replaced by Gln249 and 
Asp252. Tyr145 of human GloII is replaced by Phe as it is also the case for many other 
glyoxalases II (Cameron et al., 1999b), whereas Tyr175 and Lys143 are conserved or 
replaced by Arg, respectively. 
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Figure 18:  Model of the active sites and hydrophobic binding pocket of GloI based on the crystal 
structure of human GloI (Cameron et al., 1999a).  
(A) The putative active sites of monomeric GloI with each containing a zinc ion (given as 
sphere). (B) Model of the putative hydrophobic binding pocket of monomeric cGloI. 
A 
B
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Figure 19:  Model of tGloII and cGloII based on the crystal structure of 
human GloII (Cameron et al., 1999b).  
Residues coordinating two zinc ions are highlighted. (A) Structure of 
human GloII showing an N-terminal domain, containing 
predominantly β-strands similar to metallo-b-lactamases, and a 
smaller second domain comprising predominantly a-helices; (B) 
model of tGloII; and (C) model of cGloII. 
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Figure 20:  Model of the metal binding site of 
tGloII and cGloII based on the 
crystal structure of human GloII 
(Cameron et al., 1999b).  
Residues coordinating two zinc 
ions are highlighted. (A) Structure 
of human GloII; (B) model of 
tGloII; and (C) model of cGloII. 
 
Figure 21:  Model of the glutathione-binding site 
of tGloII and cGloII based on the 
crystal structure of human GloII 
(Cameron et al., 1999b).  
Residues involved in glutathione-
binding are highlighted. (A) Structure 
of human GloII; (B) model of tGloII; 
and (C) model of cGloII. 
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4.2 The inhibition of PfTrxR 
4.2.1 Kinetic analyses on isolated enzymes 
All 11 compounds were tested for their ability to inhibit PfTrxR and the isofunctional host 
cell enzyme hTrxR in direct comparison by Christine Nickel. The respective IC50 values 
were determined under quasi-physiological conditions, i.e., in phosphate buffer, pH 7.4, in 
the presence of 100 µM NADPH and 20 µM of the corresponding thioredoxin. Since wild 
type Trx tends to form dimers in solution which disturb the determination of exact kinetic 
constants, the hTrx mutant C72S for the studies (Irmler et al., 2002) was employed. Seven 
compounds inhibited PfTrxR with IC50 values of < 10 µM. The most potent inhibitor was 
compound 3 with an IC50 of 0.5 µM. Except for two compounds; all inhibitors were more 
effective on the parasite enzyme than on hTrxR. Compounds 1 and 2 were by a factor of 25 
and 70, respectively, more effective on PfTrxR.  
 
Table 9:  Structures of the most potent PfTrxR inhibitors; compounds 1-3 and 
corresponding IC50 values on P. falciparum TrxR and human TrxR.  
 
 
No Structure 
IC50  
PfTrxR 
[µM] 
IC50  
hTrxR 
[µM] 
Ki PfTrxR  
varied 
substrate: 
PfTrx [µM] 
Ki PfTrxR 
varied 
substrate: 
NADPH [µM] 
1 
N
S
N
NO2
 
2 50 0.65 1 
2 
N
NO2N
O2N  
2 140 n.d. n.d. 
3 
NO2
S
NO2
NO2O2N  
0.5 4 0.2 0.2 
n.d., not determined. 
 
 
Km values in the presence of varying inhibitor concentrations were determined on PfTrxR 
for both substrates, PfTrx and NADPH. For all three inhibitors, compounds 1-3; 
uncompetitive inhibition was clearly observed as Km and Vmax values decreased with 
increasing inhibitor concentrations. In accordance, Cornish-Bowden plots showed 
intercepts of all lines (obtained at different substrate concentrations) in the upper left 
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quadrant. Data for the most potent PfTrxR inhibitor 3 are shown in Figure 22. Ki values 
obtained for this uncompetitive inhibition were in the submicromolar range and are shown 
in Table 9.  
 
 
Figure 22:  Cornish-Bowden plot showing that compound 3 inhibits PfTrxR uncompetitively with 
respect to PfTrx. 
 
 
4.2.2 Effects of the inhibitors on P. falciparum in culture 
The effects of the three most potent PfTrxR inhibitors 1-3 on the growth of malarial 
parasites were tested on the chloroquine resistant P. falciparum strain K1. IC50 values - 
indicating the drug concentration required for 50% parasite growth inhibition – were 
determined to be 11 µM, 15 µM, and 18 µM, respectively. Taking into account activity 
losses due to incomplete uptake and metabolic turnover of the inhibitor, values are in good 
agreement with the kinetic data. The most effective compound on cell culture, compound 
1, was also studied using the incorporation of 3H-hypoxanthine as metabolic parameter to 
determine growth inhibition. In this assay, an IC50 value of 2.9 + 0.82 µM was determined. 
This result is in good agreement with the fact that most drugs exhibit lower IC50 values 
when assessed with this metabolic method rather than with the determination of 
parasitemia. Furthermore, drug combination assays of compound 1 with the clinically used 
antimalarials chloroquine, methylene blue, and artemisinin were carried out. Data obtained 
demonstrate that the PfTrxR inhibitor acts antagonistically with all three established 
antimalarial drugs (Figure 23). This result might indicate that compound 1 uses similar 
uptake mechanisms and/or acts on similar targets/pathways as the other three drugs. 
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Figure 23:  Convex isobologram indicating the antagonistic effects of compound 1 upon 
combination with chloroquine, methylene blue and artemisinin. 
 
 
4.3 The in vitro antimalarial effects of MB 
4.3.1 Stage-specificity of MB action 
The susceptibility of the different P. falciparum intraerythrocytic stages to MB as 
determined by the WHO microtest is given in Figure 24. The lowest IC50-values of about 
11 nM were found in the very young ring stages of the parasites indicating that this 
developmental stage is the most susceptible one. Schizonts showed the lowest 
susceptibility to the drug with IC50s as high as 88 nM. The fact that the IC50s determined in 
these experiments are higher than in the drug combination assays is based on the fact that 
the stage-specificity data were obtained by counting parasitaemia under the microscope 
whereas for the drug combinations the incorporation of 3H-hypoxanthine was determined. 
The differences in drug exposure times in both assay conditions could have played a 
significant role as the parasites were exposed to MB for only 6 hours during the microtest 
whereas in the drug combination assays they were exposed for 72 hours. 
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Figure 24:  Stage specificity of methylene blue action on the CQ resistant P. falciparum strain K1.  
IC50-values obtained for the various developmental stages of the 48 h life cycle are given. 
Data shown were derived from two parallel experiments which differed by less than 10 %. 
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4.3.2 Studies on MB uptake 
In another experiment, the uptake of MB into various compartments of parasitised (PRBC) 
and non-parasitised red blood cells (NPRBC) were studied. After incubation with MB (13, 
26, and 39 nM) and preparation of the different lysates, MB was determined by 
LC/MS/MS. The data are shown in Table 10. The total amount of MB added to the cell 
cultures could not be recovered quantitatively in the different fractions. This is most likely 
due to the various washing steps required and to the fact that MB binds strongly to surfaces 
of reaction tubes (Clark et al., 1925).  
 
Table 10:  Clearance of the medium from MB by P. falciparum parasitized 
erythrocytes 
 
MB concentration [nM] after 12 hours incubation 
Initial 
[MB] in the 
medium 
Medium 
without 
cells 
Medium of 
healthy 
erythrocytes 
Medium of 
parasitized 
erythrocytes 
Parasite 
lysate 
 
Parasite 
membrane 
pellet 
13 nM MB 6.1 4.0 <2 8.2 79 
26 nM MB 14.7 6.0 <2 16.3 152 
39 nM MB 16.6 19.2 <2 21.7 265 
 
 
4.3.3 Effects of MB upon combination with other drugs 
4.3.3.1 Combination of MB with clinically-used antimalarials 
In a parallel approach, the effects of several drug combinations including MB on the 
growth of the P. falciparum strain K1 were tested in vitro. Data are given in Table 11. The 
combinations of MB with mefloquine or quinine were additive whereas the combinations 
of MB with chloroquine (Figure 25) and all other tested quinolines as well as with 
pyrimethamine were antagonistic. A more pronounced antagonism was observed when the 
MB and chloroquine combination was performed on the chloroquine sensitive strain 3D7 
(Figure 25).  
Most interestingly, the combinations of MB with artemisinin and its derivatives artemether 
and artesunate were found to act synergistically on the CQ-resistant strain K1 (Table 11). 
The combinations of MB with artemisinin or artemether were advantageous over the 
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MB/artesunate combination. All four drugs exhibited IC50 values in the low nanomolar 
range when given alone. 
 
4.3.3.2 Combination of MB with artemisinins 
In order to investigate whether the synergistic action of MB and artemisinin derivatives 
differs between P. falciparum strains, strains with different degrees of CQ sensitivity were 
employed in the drug combination assays. Based on data obtained by Su et al. (1997) and 
our own experience, strains 3D7 and HB3 were chosen as CQ-sensitive strains while Dd2 
was chosen in addition to K1 as CQ-resistant strain. The CQ sensitivities expressed as 
IC50-values of these strains were 8.58 ± 0.43 nM, 16.82 ± 0.54 nM, 90.23 ± 10.55 nM, and 
155.17 ± 11.38 nM, respectively. The drug combinations acted synergistically on all strains 
tested as the FIC50 and FIC90-values were significantly lower than one as tested separately 
for all drug combinations (P < 0.0001). The degree of synergism was highest on the HB3 
strain (mean FIC50 = 0.59, mean FIC90 = 0.59), followed by K1 (mean FIC50 = 0.76 (P = 
0.013 describing the significance of difference when compared with HB3), mean FIC90 = 
0.78 (P = 0.0003)), and then 3D7 (mean FIC50 = 0.97 (P < 0.0001), mean FIC90 = 0.86 (P 
<0.0001)) and finally Dd2 (mean FIC50 = 0.99 (P < 0.0001), mean FIC90 = 0.90 (P = 
<0.0001)). When taking into account the FICs and isobolograms obtained (Table 12 and 
Figure 26), synergistic effects were most pronounced in the artemisinin/MB combination 
although artemether and artesunate were more potent than artemisinin when given as 
monotherapy (see IC50 values in Table 12). FIC-values for the three different artemisinins 
in combination with MB were reproducibly lowest for artemisinin (mean FIC50 = 0.64, 
mean FIC90 = 0.62) in comparison with artesunate (mean FIC50 = 1.00 (P = 0.0001); mean 
FIC90 = 0.88 (P = 0.0001)) and artemether (mean FIC50 = 0.82 (P = 0.0008). FIC50s were 
reproducibly lowest at combination ratios of 3:1 (mean FIC50 = 0.69) than at a combination 
ratio of 1:1 (mean FIC50 = 0.80; P = 0.049) or 1:3 (mean FIC50 = 0.98; P = 0.0001). Thus, 
only low MB concentrations are required for maximal therapeutic effects. 
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Table 11:  Effects of combination of MB with clinically-used antimalarials  
 
 
Drugs given in 
combination 
IC50 in nM IC90 in nM 
Mean FIC50 value at 
fixed partner:MB 
ratio 
Type of Combination 
Effect 
 
Artemether 
 
1.8 ± 0.1 3.7 ± 0.1 
0.75 at 1:1 
0.65 at 1:3 
0.65 at 3:1 
Synergism 
 
Artesunate 
 
1.3 ± 0.2 3.1 ± 0.2 
0.85 at 1:1 
1.00 at 1:3 
0.90 at 3:1 
Additive effect / 
Synergism 
 
Artemisinin 
 
4.0 ± 0.8 8.0 ± 0.6 
0.67 at 1:1 
0.73 at 1:3 
0.73 at 3:1 
Synergism 
CQ 
(4-aminoquinoline) 
117 ± 27 199 ± 30 
1.28 at 1:1 
1.18 at 1:3 
1.25 at 3:1 
Antagonism 
Piperaquine 
(Bisquinoline) 
10.6 ± 2.7 20.6 ± 1.8 
1.97 at 1:1 
1.94 at 1:3 
2.01 at 3:1 
Antagonism 
Amodiaquine 
(4–aminoquinoline) 
7.8 ± 1.4 12.1 ± 0.4 
1.60 at 1:1 
1.20 at 1:3 
1.05 at 3:1 
 
Antagonism 
Quinine 
(quinoline 
methanol) 
90 ± 39 227 ± 82 
0.97 at 1:1 
1.05 at 1:3 
0.97 at 3:1 
Additive effect 
Mefloquine 
(quinoline 
methanol) 
7.8 ± 2.0 15.7 ± 2.5 
1.04 at 1:1 
1.03 at 1:3 
1.09 at 3:1 
Additive effect 
Primaquine 
(8-aminoquinoline) 
1820 ± 40 3860 ± 560 
1.22 at 1:1 
1.17 at 1:3 
1.12 at 3:1 
Antagonism 
Pyrimethamine 
(antifolate) 
7540 ± 810 16700 ± 880 
1.02 at 1:1 
1.52 at 1:3 
1.41 at 3:1 
Antagonism 
*IC values for the partner drugs of MB (columns 2 and 3) are means of at least two independent assays 
conducted on different days. For MB itself IC50 is 6.5 ± 1.8 nM and IC90 is 12.4 ± 2.3 under the chosen 
conditions. FIC50 values were determined according to the fixed-ratio method of Fivelman et al. (2004). 
FIC50 < 1 indicates synergistic drug action; FIC50 = 1, additive action; FIC50 > 1, antagonistic action.  
FIC50 A = [IC50 (A + B)]/IC50 A; FIC50 B = [IC50 (B + A)]/IC50 B; FIC50 = FIC50 A + FIC50 B (Ohrt et al., 
2002). 
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Figure 25:  FIC50 (left) and FIC90-values (right) of MB and CQ determined at various dosage 
ratios (1:1, 1:3, and 3:1) and in independent experiments (indicated by the lines) on 
CQ-resistant (K1) and CQ-sensitive (3D7) strains of P. falciparum.  
The resulting antagonistic effect of the drug combination is indicated by the convex 
isobolograms. 
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Figure 26:  FIC50 (left) and FIC90 values (right) of MB and artemisinin at various fixed dosage 
ratios on different P. falciparum strains.  
All data points were plotted to represent the complete range of interactions seen at the 
concentration ratios evaluated instead of presenting individual representative 
isobolograms. The concave isobolograms for these data points indicate a synergistic effect 
of the combination. A characteristic curve can be drawn for the triangles representing the 
strain HB3. 
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FIC90 
0.70 ± 0.14 
0.70 ± 0.10 
0.57 ± 0.12 
0.75 ± 0.21 
0.80 ± 0.10 
0.90 ± 0.14 
0.50 ± 0.10 
0.95 ± 0.07 
0.73 ± 0.06 
0.55 ± 0.07 
 0.37 ± 0.06 
 0.55 ± 0.07 
 
1.3 
1.1 
1.9 
1.0 
 
1.2 
N.D 
N.D 
1.5 
 
Sum (3:1 ratio) 
FIC50 
0.65 ± 0.07 
0.70 ± 0.14 
0.53 ± 0.12 
0.70 ± 0.14 
0.90 ± 0.14 
1.05 ± 0.07 
0.55 ± 0.07 
1.00 ± 0.28 
0.73 ± 0.06 
0.50 ± 0.10 
0.43 ± 0.06 
0.60 ± 0.28 
2.0 
1.4 
1.6 
1.2 
1.3 
N.D 
N.D 
1.9 
FIC90 
0.90 ± 0.14 
1.20 ± 0.10 
0.80 ± 0.17 
1.10 ± 0.14 
0.95 ± 0.07 
1.15 ± 0.07 
0.90 ± 0.14 
1.10 ± 0.10 
0.77 ± 0.21 
0.95 ± 0.07 
0.63 ± 0.15 
0.80 ± 0.28 
1.3 
1.2 
1.2 
1.8 
1.1 
N.D 
N.D 
1.5 
Sum (1:3 ratio) 
FIC50 
0.65 ± 0.21 
1.35 ± 0.35 
0.80 ± 0.17 
1.25 ± 0.21 
1.00 ± 0.10 
1.30 ± 0.14 
0.80 ± 0.14 
1.55 ± 0.07 
0.73 ± 0.15 
0.95 ± 0.07 
0.60 ± 0.10 
0.90 ± 0.14 
1.9 
1.4 
1.5 
1.3 
1.2 
N.D 
N.D 
1.4 
FIC90 
0.80 ± 0.14 
0.90 ± 0.10 
0.63 ± 0.12 
0.95 ± 0.21 
0.70 ± 0.10 
1.05 ± 0.07 
0.55 ± 0.07 
1.00 ± 0.10 
0.70 ± 0.10 
0.70 ± 0.10 
0.43 ± 0.06 
0.55 ± 0.07 
1.3 
1.2 
1.9 
2.0 
 
1.3 
N.D 
N.D 
1.6 
Sum (1:1 ratio) 
FIC50 
0.75 ± 0.21 
1.00 ± 0.14 
0.63 ± 0.12 
0.95 ± 0.35 
0.85 ± 0.07 
1.25 ± 0.07 
0.50 ± 0.14 
1.30 ± 0.14 
0.67 ± 0.06 
0.65 ± 0.07 
0.47 ± 0.12 
0.65 ± 0.21 
2.0 
1.5 
1.9 
2.0 
1.3 
N.D 
N.D 
1.9 
MB 
7.94 ± 0.35 
5.24 ± 0.18 
4.98 ± 2.59 
3.26 ± 0.57 
5.45 ± 2.05 
6.00 ± 0.32 
6.10 ± 3.46 
2.99 ± 0.34 
6.37 ± 1.10 
5.72 ± 0.06 
3.84 ± 0.24 
3.22 ± 0.21 
5.7 
6.2 
3.5 
5.8 
6.4 
N.D 
N.D 
4.0 
IC50 in nM 
Test 
Drug 
1.76 ± 0.07 
8.40 ± 1.63 
5.10 ± 0.83 
5.87 ± 0.45 
1.28 ± 0.16 
5.22 ± 0.40 
6.49 ± 0.81 
4.35 ± 0.29 
3.98 ± 0.77 
20.36 ± 2.09 
13.67 ± 2.92 
17.29 ± 1.53 
8.7 
16.6 
17.2 
17.6 
117 
N.D 
N.D 
8.8 
Plasmodium 
falciparum 
strains tested 
K1 
Dd2 
HB3 
3D7 
K1 
Dd2 
HB3 
3D7 
K1 
Dd2 
HB3 
3D7 
K1 
Dd2 
HB3 
3D7 
K1 
Dd2 
HB3 
3D7 
Table 12 :   In vitro drug combination assays of the artemisinins, piperaquine and chloroquine with MB on P. falciparum 
                        strains with different CQ sensitivity. 
 
Drug 
Artemether 
Artesunate 
Artemisinin 
Piperaquine 
Chloroquine 
Values are means of at least two independent assays carried out on different days. However, values from piperaquine/MB and chloroquine/MB were obtained 
from single experiments. When FIC50 < 1, synergistic drug action; FIC50 = 1, additive action; FIC50 >1, antagonistic action.  
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4.4 The characterization of PfLipDHs 
Bioinformatic analysis of the two PfLipDH genes revealed putative mitochondrial and 
apicoplastic target sequences for PfLipDH1 and PfLipDH2, respectively. The PfLipDH1 
gene encodes a protein of 513 amino acids and a theoretical mass of 57 kDa while the 
PfLipDH2 gene encodes a larger protein of 666 amino acids and a molecular mass of 75.6 
kDa. Both genes of PfLipDH1 and PfLipDH2 present on chromosome 12 and 8, 
respectively, of the P. falciparum genome were successfully amplified by PCR and cloned 
into appropriate expression vectors (pQE30 and pRSET-A). Both expression vectors 
allowed the overexpression of the respective genes as six-histidyl tagged proteins making 
possible the purification of the PfLipDHs by affinity chromatography on Ni-NTA columns. 
Several E. coli strains were used in order to optimise the overexpression process (Table 4). 
Yields of both PfLipDHs obtained after overexpression and purification were however 
very small. Active PfLipDH1 was obtained with a low purity of about 30% after 
overexpression in E. coli M15 cells. Identity of PfLipDH1 was also demonstrated by 
western blot analysis with anti-histidine tag antibodies. In other overexpression systems, 
PfLipDH1 was either obtained in inclusion bodies or was not overexpresed at all (Table 4). 
Attempts to purify PfLipDH1 from inclusion bodies by denaturation and subsequent 
renaturation in appriopriate buffer systems were not successful either. PfLipDH2 could not 
be overexpressed in the various overexpression systems tested. 
A kinetic characterization of PfLipDH1 – which was also obtained in low amounts only – 
as well as the intraparasitic localization studies of both PfLipDHs was reported in 
McMillan et al. (2005). 
Based on previous knowledge that MB inhibits lipoamide dehydrogenases from other 
sources (e.g. from trypanosomes), the inhibitory effects of MB on PfLipDH1 was tested. 
However, the preliminary results indicated that MB acts more as a substrate for PfLipDH1 
than as an inhibitor. 
 
4.5 Glutathionylation of PfTrx 
Mass spectrometric analysis of the tryptic digests of GSSG-treated and control PfTrx 
revealed two distinct glutathionylated peptides whose masses corresponded to theoretically 
calculated glutathionylated peptides of PfTrx. Both peptides (peptide 1 and 2 – Figure 27) 
spanning Ile47 and Lys60, and Arg46 and Lys60, respectively indicated that the 
glutathionylated cysteine was Cys54. Mass spectra of peptides 1 and 2 from PfTrx treated 
with and without GSSG are shown below (Figure 28). Based on the relative intensities of 
Results 78
the glutathionylated peptides to the intensities of the non-glutathionylated peptides in the 
spectrum of the treated sample it could be estimated that roughly 70% of PfTrx was 
glutathionylated under the conditions tested. 
Glutathionylated PfTrx could also be identified by western-blot analysis using anti-
glutathione antibodies. However, results of the experiment could not be effectively 
reproduced on subsequent trials and are therefore not shown. 
 
 
 
 
 
 
 
 
 
 
Figure 27:  Amino acid sequence of recombinant hexa-histidyl-tagged PfTrx indicating the two 
peptide fragments spanning the glutathionylated Cys54 (red) of interest. 
 
 
 
 
 
MRGSHHHHHH GSVKIVTSQS EFDSIISQNE  30 
            ______2_________ 
LVIVDFFAEW CGPCKRIAPF YEECSKTYTK  60 
               1 
MVFIKVDVDE VSEVTEKENI TSMPTFKVYK  90 
 
 NGSSVDTLLG ANDSALKQLI EKYAA 115 
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Figure 28:  MALDI-TOF mass spectra of PfTrx peptides.  
A). Peptide 1 generated from GSSG-treated PfTrx. The mass is corresponding to the 
glutathionylated peptide Ile47–Lys60: IAPFYEEC*SKTYTK. B). Corresponding 
spectrum trace of the non-treated sample corresponding to the non-glutathionylated 
peptide 1: IAPFYEECSKTYTK. C). Peptide 2 Arg46–Lys60: RIAPYEEC*SKTYTK 
generated from GSSG-treated PfTrx. D). Corresponding spectrum trace of the non-treated 
sample corresponding to the non-glutathionylated peptide 1: RIAPFYEECSKTYTK. 
 
 
 
 
 
 
 
RIAPYEEC*SKTYTK IAPFYEEC*SKTYT
A C
B D
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5 Discussion 
 
Records of malaria date back to the earliest human civilizations when it was described as 
the distinct periodic fevers. Malaria is a serious infection with Plasmodium parasites, 
which are spread by the bite of Anopheles mosquitoes. For this reason, nearly all malaria 
control strategies target either the parasite or the mosquito. Inspite of worldwide efforts, 
however, an eradication of malaria is far from being achieved. There are no fewer than 
four species of Plasmodium that infect people, each with thousands of genetic variants, and 
about thirty-five different species of malaria-transmitting mosquitoes. It is the complex 
diversity of the parasites, the mosquitoes, the local ecologies, socio-economic conditions, 
and human responses to disease that conspire to make malaria notoriously hard to control. 
As a result, there is no single prescription which can successfully control malaria in all 
areas. 
Malaria was described by Robert Desowitz as “the oldest emerging disease”. The disease is 
not only well-known as one responsible for the death of an African child approximately 
every 20 seconds but also as one that has baffled the minds and brains of many profound 
scientists. According to Desowitz, the much heralded malaria vaccine is a goal, an illusion 
that has not been realized and may never be realized in combating the disease at a 
population level (Desowitz, 2004). This understatement came up after hundreds of millions 
of dollars, the energies and resources of some of the best scientific minds have been – and 
still are – devoted to an intensified malaria vaccine research in the past 30 years. The 
accuracy of malaria re-emergence – as described by Desowitz – stems from the acquisition 
of increasing resistance by the parasites to almost all available clinically-used antimalarial 
drugs and the Anopheles mosquitoes to insecticides. Antimalarial drug resistance is 
worsening, with the geographic spread of resistance widening to previously unaffected 
areas and a remorseless increase both in the prevalence and degree of drug resistance. 
Chloroquine-resistant P. falciparum now predominates in Southeast Asia, South America 
and increasingly in Africa. Sulfadoxine-pyrimethamine resistance is widespread in Asia 
and South America, and increasingly in Africa (Roper et al., 2005). Southeast Asia is now 
well-known as the epicentre for multi-drug resistant P. falciparum malaria (Yeung et al., 
2004). Chloroquine and the alternative sulfadoxine-pyrimethamine are cheap, safe and 
previously highly effective. By mechanisms such as mutations in target genes 
(sulfadoxine-pyrimethamine), decreased accumulation of a drug within the parasite 
(including increase in efflux – quinolines) and upregulation of target genes (P. falciparum 
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multiple drug resistance (Pfmdr) gene); these drugs are increasingly being rendered useless 
in the treatment of malaria. Factors affecting parasite resistance can be categorized as 
pharmacological, host parasite and operational (Figure 29; Olliaro, 2005). 
 
 
Figure 29:  Factors affecting parasite resistance.  
Varieties of factors contribute to, and have an impact on, the development of resistance in 
the malarial parasite, including pharmacological, host-parasite, and operational factors. 
Pharmacological factors include the drug’s pharmacokinetic and pharmacodynamic 
characteristics, as well as its intrinsic propensity to generate resistance. Host-parasite 
factors include epidemiology and transmission intensity (the higher the entomological 
inoculation rate, the higher the chance of being infected and diseased early in life but also 
the sooner immunity develops and the more diverse the genetic pool; in areas of low 
transmission, resistance, once established tends to spread more rapidly) and operational 
aspects (inadequate drug treatment policies, irrational prescribing and drug use, 
uncontrolled drug market, counterfeit products, and noncompliance) (adapted from 
Olliario, 2005). 
 
 
With the exception of the artemisinins, resistance to all known antimalarials has been 
reported. Given the inexorable spread of drug resistance, and until the development of an 
effective antimalarial vaccine, the search for effective, safe, and affordable drugs for 
falciparum malaria is one of the most pressing health priorities worldwide. New 
antimalarial drugs must meet the requirements of rapid efficacy, minimal toxicity and low 
cost. 
 
5.1 The glyoxalase system 
In an initial development project for new drugs with new mechanisms of action against the 
P. falciparum parasite, the glyoxalase system was exploited for rational drug design. Over 
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the last years the glyoxalase system has received increasing attention as a 
chemotherapeutic target for antitumour drug development. Several compounds interfering 
with the glyoxalase system have been shown to inhibit the growth of cancer cells in vitro 
and in vivo (Hamilton and Creighton, 1992; Creighton et al., 2003). Blood stages of the 
malarial parasite P. falciparum are highly proliferative and of high glycolytic activity thus 
depending on the glyoxalase system for the detoxification of methylglyoxal. Inhibition of 
this system within the parasite therefore provides a promising chemotherapeutic strategy 
(Thornalley et al., 1996). 
As reported in this thesis, a complete glyoxalase system in P. falciparum comprising at 
least one GloI and two GloII isoenzymes has been characterized and direct structural and 
functional comparisons with the isofunctional human host enzymes have been carried out.  
cGloI and cGloII seem to be localized in the cytosol and act together as the major defense 
line against toxic 2-oxoaldehydes. In direct comparison with the respective host enzyme, 
cGloI shows a three times lower Km for methylglyoxal-GSH and a slightly higher specific 
activity. Also the Km of cGloII is by a factor of at least 2 lower than for human GloII and 
the kcat value is more than two times higher. This indicates the need for an efficient 
methylglyoxal detoxification in the malarial parasites. Both glyoxalases start to act in the 
lower micromolar range. The involvement of Tyr185 in the catalysis of cGloII was studied 
by site directed mutagenesis. In analogy to human GloII (Ridderström et al., 2000) Tyr185 
was proven to contribute to substrate binding as reflected by a 2.5 fold increase in Km. 
tGloII carries a putative apicoplast import sequence and also GILP is preceded by a 
targeting sequence which might direct the protein to the apicoplast and/or the 
mitochondrion. This fact points to the possibility that the apicoplast, a bacteria derived cell 
organelle of Plasmodium, possesses glyoxalase activity and pathways generating toxic 2-
oxoaldehydes. The catalytic properties of tGloII are comparable to human GloII. For 
GILP, however, no typical glyoxalase activity could be determined the physiological 
substrate remaining unknown. This fact is of particular interest since GILP is only present 
and highly conserved in Plasmodium species. Highest sequence identities with proteins 
from other species were only 25% with A. thaliana, other plants having a monomeric large 
GloI, and photosynthetic bacteria, which have the dimeric form of small GloI. These 
observations strongly suggest GILP as a promising target for the development of specific 
antiparasitic drugs and a diagnostic tool for clinical and epidermiological studies. 
Furthermore, they point to the "green origin" of Plasmodium. The function of GILP will be 
studied in further detail. 
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As a basis for further inhibitor development, different S-(N-hydroxy-N-arylcarbamoyl) 
glutathione derivatives were tested as P. falciparum GloI and GloII inhibitors. The 
compounds acted as strong competitive inhibitors of both Glo isoenzymes – on cGloI in 
the nanomolar range and on tGloII and cGloII in the micromolar range (Table 5). The 
inhibitors had originally been synthesized as inhibitors of GloI and slow substrates of GloII 
based on the very low GloII activity in tumour cells compared to normal cells (Murthy et 
al., 1994). The fact that the S-(N-hydroxy-N-arylcarbamoyl)glutathiones are substrates for 
mammalian glyoxalase II but not for P. falciparum glyoxalases II indicates that these 
compounds might selectively inhibit human glyoxalases since normal human cells – in 
contrast to malarial parasites - would be able to hydrolyse the inhibitor. Tight binding of 
the inhibitors to the enzymes arises in part from mimicking the stereoelectronic features of 
the enediol intermediate formed from the methylglyoxal-glutathione-hemithioacetal that 
acts as a substrate for GloI and also in part by the interaction of the N-aryl substituent with 
a hydrophobic pocket at the active site of GloI (Cameron et al., 1999a). The latter reason is 
clearly supported by the increase in binding affinity with increase in hydrophobicity of the 
inhibitors which is further supported by our data. An alignment of the amino acid 
sequences of human GloI and cGloI showed that 80% of the residues involved in the 
composition of the hydrophobic binding pocket of human GloI are conserved in cGloI 
(Figures 13 and 18B). HBPC-GSH showed a lower Ki value for cGloII than for human 
GloII and could thus serve as a starting point for the development of more selective 
inhibitors.  
Unexpectedly, S-p-bromobenzylglutathione, the diethyl ester prodrug form of which has 
been demonstrated to inhibit the growth of P. falciparum in vitro (Thornalley et al., 1994), 
is a weak cGloI inhibitor with a Ki of 20 µM. A much stronger competitive inhibition is 
observed for human GloI the Ki value being in the range of 0.17 µM (Murthy et al., 1994; 
Aronsson et al., 1981; and results from this study). This strongly indicates that the 
antiparasitic effects of the compound are not primarily based on the inhibition of the 
parasite glyoxalase system but of other enzymes, or on interference with the human 
methylglyoxal detoxification in red cells. 
With the characterization of a complete, functional, and most likely essential glyoxalase 
system in Plasmodium falciparum a novel potential target for antimalarial drug 
development has become accessible. First inhibitor studies revealing inhibition in the 
nanomolar range and the identification of a novel GloI-like enzyme which is likely to be 
unique for malarial parasites represent most promising steps towards the possibility of 
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specific interference with this pathway. Furthermore, the emergence of suitable prodrug 
forms of the S-(N-hydroxy-N-arylcarbamoyl)glutathiones which mask their diacid nature 
thus allowing membrane permeation are most encouraging for successful drug 
development. 
One great advantage for exploiting the glyoxalase system of P. falciparum as a therapeutic 
target is that the host enzyme is also being targeted for the development of drugs for 
cancer. As a result, the cost of plasmodial antiglyoxalase drug discovery can be greatly 
reduced because initial work directed towards more profitable targets, have been 
undertaken. Most of the inhibitors used in this study were based on previous knowledge 
acquired from the application of the inhibitors on the glyoxalase system of cancer cells. In 
fact, the S-(N-hydroxy-N-arylcarbamoyl)glutathiones were kindly provided to us by 
Professor Donald J. Creighton (Maryland, USA) who is involved in the design and 
development of new classes of tumoricidal agents that specifically target the glyoxalase 
detoxification pathway in order to induce elevated concentrations of cytotoxic 
methylglyoxal in tumour cells. More potent bivalent transition state analogs of S-(N-
hydroxy-N-arylcarbamoyl)glutathiones have shown Ki values as low as 1 nM for human 
glyoxalase I. All presently known glyoxalase inhibitors – bivalent and monovalent analogs 
of S-(N-hydroxy-N-arylcarbamoyl)glutathiones, S-aryl and S-alkyl GSH derivatives, 
dicarbonyl GSH derivatives – coupled with the to-be-known structures of P. falciparum 
glyoxalases would serve as lead structures in the design of P. falciparum selective 
glyoxalase inhibitors. Prodrug strategies for the efficient delivery of inhibitors into 
plasmodial cells both in vitro and in vivo also stand to benefit. 
 
5.2 The thioredoxin system 
PfTrxR like human TrxR belongs to the high molecular weight group of TrxRs which 
contain an FAD moiety linked to an internal redox center and another C-terminally located 
redox center in each subunit of the homodimeric protein (Williams et al., 2000). Electrons 
are shuttled from the FAD via an internal redox-active disulphide to the flexible C-
terminally located redox center of the other subunit in the dimeric enzyme. The reduced C-
terminal active site is then highly accessible for reducing substrates. However, hTrxR like 
other mammalian TrxRs contains a highly reactive selenocysteine residue at its C-terminal 
redox site. The fact that – in spite of the high reactivity of the selenocysteine-containing 
hTrxR – a selective PfTrxR inhibition could be achieved, points to the involvement of 
other binding moieties than the C-terminal redox center.   
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To study the mechanism of inhibition in more detail different approaches were made. For 
the most interesting compounds 1, 2, and 3 the inhibition of the closely related enzyme 
glutathione reductase were tested and Ki values and the type of inhibition with respect to 
the physiological substrates Trx and NADPH were determined. GR is a homodimeric 
FAD-dependent enzyme which is structurally and mechanistically closely related to TrxR. 
The most prominent difference between the two enzymes is the absence of the second, the 
C-terminal, redox-active site in GR (Williams et al., 2000). In GR the substrate glutathione 
is directly reduced at the N-terminal redox center. PfGR has been well characterized and 
closely resembles its human counterpart. The results obtained on hGR and PfGR indicate 
that at inhibitor concentrations leading to 50 % PfTrxR inhibition (namely 2 µM, 2 µM, 
and 0.5 µM) compounds 1-3 lead to quite efficient inhibition between 18 % and 81 % for 
hGR and between 39 % and 69 % for PfGR. This result further supports the theory that the 
inhibitors do not significantly interact with the C-terminal redox center of TrxR but rather 
with other structural motifs or amino acid residues, possibly the intersubunit region, which 
are similar in PfTrxR and GRs. 
All three compounds showed uncompetitive inhibition on PfTrxR with Ki values in the 
submicromolar range. This indicates that the inhibitors bind to one of the enzyme-substrate 
intermediate complexes that occur during catalysis, as previously observed for 1-chloro-
2,4-dinitrobenzene with hGR (Bilzer et al., 1984). 
In the earlier attempt to selectively inhibit PfTrxR with mannich bases, irreversible 
inactivation of the PfTrxR by bisalkylation of α,β-unsaturated mannich bases of the C-
terminal thiols was postulated after observation of competitive inhibition with DTNB 
(Davioud-Charvet et al., 2003). The inhibitors in the present study act uncompetitively and 
to approximately equal extents in the presence of both physiological substrates of PfTrxR. 
All compounds tested were active on malarial parasites in the low micromolar range. 
Taken together, these data indicate that specificity for PfTrxR over hTrxR can be achieved 
by inhibitors that bind differentially to the enzyme-substrate complex. A possible binding 
site of these inhibitors is the interface between the two subunits of the enzyme – a 
hypothesis that should be verified and utilized for further inhibitor development. 
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5.3 Methylene blue in antimalarial chemotherapy 
 
Methylene blue has been employed as a lead compound for antimalarial research for over a 
century as antimalarial quinolines like chloroquine and amodiaquine are being synthesized 
based on modification of the MB chromophore (Wainwright and Amaral, 2005). Use of 
MB in the treatment of malarial patients contributed to the birth of chemotherapy in the 
late 1800s. Toxicity reports after intake of MB led to its withdrawal as an antimalarial in 
the mid 1900s especially as other active and less toxic drugs like chloroquine and quinine 
became available at the time. With the increasing development of resistance by parasites to 
these quinolines as well as other antimalarial drugs, a renaissance of interest in the 
antimalarial properties of MB has been developed. Toxicity episodes after MB 
consumption are now highly linked to persons with certain levels of glucose-6-phosphate 
dehydrogenase deficiency. Several phenothiazinium derivatives of MB like azure B and 
new methylene blue have been developed (Atamna et al., 1996). These derivatives are 
however more potent as antibactericidal drugs than as antimalarials (Vennerstrom et al., 
1995; Wainwright et al., 1998). Intrinsically, MB is promising as antimalarial drug acting 
in vitro in the nanomolar range and in patients in the micromolar range (Atamna et al., 
1996; Mandi et al., 2005). 
Stage specificity experiments indicated that MB sensitivity parallels the shift in metabolic 
processes during development of the parasite. The developmental cycle of P. falciparum in 
erythrocytes lasts 48 hours, involving a gradual progression from early to late rings (0 – 24 
h), small, pigmented to large uninuclear trophozoites (24 – 38 h) and binucleate to 
segmenting schizonts (38 – 48 h). As indicated by the studies on stage specificity of MB 
action, young ring stages of P. falciparum with low metabolic rates show the highest 
susceptibility to the drug while the trophozoites and schizonts which are involved in 
protein synthesis and nuclear division, respectively, show lower susceptibilities. The 
differences in IC50 values are as high as a factor of 8.  
In addition, the uptake of MB into various compartments of PRBC and NPRBC was 
studied (Table 10). The half-life of MB in the blood after intravenous administration was 
estimated to be 5.25 h (Peter et al., 2000). Thus in cell culture it is likely to be much 
longer. The MB concentrations in the medium of PRBC were repeatedly below the 
detection limit of 2 nM whereas the medium of NPRBC showed concentration dependent 
MB levels. This indicates that MB is taken up particularly by PRBC and is thus available 
for antiparasitic activity. This hypothesis is further supported by the fact that in the parasite 
lysates a higher MB concentration was determined than in the medium. In the parasite 
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membrane pellet the accumulation was even more pronounced (factor 9-12). Lysates of 
PRBC and NPRBC had MB concentrations below 4 nM. Thus, the data demonstrate 
selective uptake of MB by malarial parasites and indicate that concentrations required for 
efficient turncoat inhibition of PfGR can be reached in Plasmodium. 
The activity of MB against P. falciparum glutathione reductase (PfGR, Farber et al., 1998), 
led to its recent suggestion as an adjuvant drug for use with chloroquine (Becker et al., 
2003) as chloroquine resistant parasites of P. falciparum have been shown to possess 
higher amounts of reduced GSH. Moreover, double drug conjugates of CQ and the 
selective PfGR inhibitor 6-[2-(3-methyl)-naphthoquinolyl]hexanoic acid restricted the 
growth of Plasmodium species both in vitro and in vivo (Davioud-Charvet et al., 2001). 
The present study on the antimalarial effects of MB was triggered by the fact that a clear 
advantage of the MB/CQ combination over MB monotherapy could not be observed during 
field trials in the Nouna district of Burkina Faso (Mandi et al., 2005; Meissner et al., 
2005). In vitro combinations of MB with CQ as well as with other clinically-used 
antimalarials were therefore tested in a search for potential clinical drug combination 
therapies and also to facilitate the design of future field studies. 
The combinations of MB with mefloquine or quinine were additive whereas the 
combinations of MB with chloroquine (Figure 25) were antagonistic. A significant positive 
correlation was detected between the IC50 values of CQ and MB (r = 0.701, P = 0.0001) 
indicating an increased likelihood for cross resistance. The antagonistic action of 
chloroquine and methylene blue were also shown for the chloroquine sensitive strain 3D7 
(Figure 25). The mode of action of CQ involves the inhibition of haem polymerization into 
non-toxic haemozoin (Ridley et al., 1997). MB has been reported to inhibit growth of P. 
falciparum through pleiotropic mechanisms (Schirmer et al., 2003) involving nucleic acid 
intercalation, food vacuole basification, parasite redox cycle interference and haem 
polymerization inhibition (Atamna et al., 1996) in addition to its inhibitory effects on 
PfGR. Thus one could speculate that a similar mode of action concerning haem-
polymerization explains the antagonistic effects of the drugs. Since MB is taken up by the 
parasite passively, a competition for uptake mechanisms is unlikely to explain this 
phenomenon. The effect of MB on glutathione reduction (Ginsburg and Golenser, 2003) is 
probably reflected in the observation that the antagonism between MB and CQ is less 
pronounced for the CQ resistant strain K1 than for the sensitive strain 3D7.  
However, synergistic drug combinations were observed upon combination of MB with all 
three artemisinins i.e. artemisinin, artesunate and artemether. However, the highest degree 
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of synergism was observed with the artemisinin/MB combination (Table 12 and Figure 26) 
at a fixed concentration ratio of 3:1. 
Artemisinins are now the focus of international attention as the frontline defense against 
resistant falciparum malaria (Yeung et al., 2004). They represent a new family of 
compounds, with a novel mode of action and faster antimalarial activity than any of the 
other drugs (Nosten and Brasseur, 2002). They have proven themselves robust over at least 
a decade of consistent use in Asia, in terms of effectiveness, safety and in the lack of any 
documented drug resistance (Haynes and Krishna, 2004). To date, there have been no 
reported cases of stable, clinically relevant genetic resistance to artemisinin, although 
tolerance can be produced through repeated in vitro culture of parasites in the presence of 
the drug (Meshnick, 2002). 
The evolution of drug resistance is an inevitable consequence of genetics and natural 
selection when drugs are used against parasites. As effective and robust as the artemisinin 
are today, it is only a matter of time before genetically resistant strains emerge and spread. 
The key, therefore, to preserving the artemisinins is to eliminate their routine use as 
monotherapies, and to treat patients with uncomplicated malaria (the vast majority of 
cases) with artemisinin-based combination therapies (ACTs) instead (Woodrow et al., 
2005, Khan et al., 2004). ACTs constitute a combination of an artemisinin derivative with 
another unrelated anti-malarial drug, ideally coformulated in a single pill so that individual 
drugs can not be knowingly or inadvertently used as monotherapies. Combining drugs in 
this way – already a practice in the treatment of tuberculosis and HIV/AIDS infection, 
minimizes the likelihood that a single parasite with drug resistance will propagate and 
spread.  
According to Nosten and Brasseur (2002), an ideal drug combination should have the 
following characteristics. 
• Components have different modes of action 
• No interactions 
• Short course regimens (3 days at most) 
• At least one drug which clears asexual forms rapidly 
• At least one drug with long half-life (> 4 days) 
• Well tolerated, low toxicity 
• Broad spectrum of action (including against gametocytes) 
• Coformulation possible 
• Inexpensive 
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The artemisinin/MB combination at a fixed dose ratio meets all but one of the above 
characteristics. In this combination, neither artemisinin nor MB has a half-life greater than 
4 days. The half life of the artemisinins is usually very short with that of artemisinin being 
only 2-3 hours (Davis et al., 2005). The half life of MB is also not much longer, only 6 
hours (Peter et al., 2000). However, in Africa where transmission rates of the disease are 
high, a partner drug for the artemisinins with a very long half life may be unsuitable as 
subsequent infections could occur before the partner drug is cleared from the circulation 
but after the artemisinins have long been cleared (Ridley, 2002). Resistance is more likely 
to develop against the partner drug in such a situation. In the artemisinin/MB, the parasites 
would be exposed to subtherapeutic concentrations for only a short time, thereby deterring 
the emergence of resistance to any of the partner drugs as the selection pressure for 
resistance would be lowered. A similar currently-in-use drug combination Lap-dap – 
consisting of chlorproguanil and dapsone – whereby both partner drugs also have short 
halflives showed a much slower parasitic resistance development in clinical studies in East 
Africa in comparison to the similarly acting sulfadoxine-pyrimethamine drug combination 
with longer halflives (Wiesner et al., 2003). However, although the short halflives of both 
artemisinin and MB would warrant longer treatment duration, the period of treatment could 
greatly be reduced in comparison to artemisinin monotherapy thereby reducing the 
problem of compliance to treatment. Otherwise, the other aspects of an ideal drug 
combination can be reached by the proposed artemisinin/MB combination. Both partner 
drugs have different modes of action and according to the correlation analysis of their IC 
values, there is no form of interaction between artemisinin and MB as both drugs are 
highly negatively correlated. This indicates a less likelihood of cross resistance 
development between MB and artemisinin. 
Spread of drug resistance is facilitated by the exposure of malarial parasites to sub-
therapeutic levels of antimalarial drugs, that kill sensitive parasites but allows parasites 
with a resistance mutation to survive and reproduce. With this in mind, the following 
instructions for application of the Artemisinin/MB combination are recommended in order 
to reduce the risk of a possible emergence and spread of drug resistance to it. 
 
• The combination should be taken at a sufficient dose and over a sufficient duration. 
• Restriction of usage to patients with a definitive diagnosis of malaria. 
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• Restriction of usage to patients who are compliant with respect to the treatment 
regimen. 
• Sale of the drug only in pharmacies to avoid the use of ineffective duplicate 
formulations 
 
5.4 Glutathionylation of PfTrx 
The Cys54 residue of PfTrx was shown to be glutathionylated on two different peptide 
fragments obtained upon tryptic digest of GSSG-treated PfTrx. As was the case with 
human Trx (Casagrande et al., 2002), a possible crosstalk between the thioredoxin and 
glutathione systems could be shown to exist in P. falciparum. Involvement of the redox 
active cysteines (Cys41 and Cys44) in glutathionylation could not be shown, implying that 
modification of the functions of PfTrx upon glutathionylation is unlikely. However, 
involvement of the cys54 in dimerization or polymerization of PfTrx as well as in 
interaction with other proteins can not be ruled out.  
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